Mouse Models in PWS Research | Encyclopedia MDPI

Mouse Models in PWS Research: History

Please note this is an old version of this entry, which may differ significantly from the current revision.

Subjects: Pathology

Contributor: Timofey Rozhdestvensky , Delf-Magnus Kummerfeld , Carsten Raabe , Boris V. Skryabin

Prader-Willi syndrome (PWS) is a neurogenetic multifactorial disorder caused by the deletion or inactivation of paternally imprinted genes on human chromosome 15q11-q13. The affected homologous locus is on mouse chromosome 7C. The positional conservation and organization of genes including the imprinting pattern between mice and men implies similar physiological functions of this locus. Therefore, considerable efforts to recreate the pathogenesis of PWS have been accomplished in mouse models. We provide a summary of different mouse models that were generated for the analysis of PWS and discuss their impact on our current understanding of corresponding genes, their putative functions and the pathogenesis of PWS. Murine models of PWS unveiled the contribution of each affected gene to this multi-facetted disease, and also enabled the establishment of the minimal critical genomic region (PWScr) responsible for core symptoms, highlighting the importance of non-protein coding genes in the PWS locus. Although the underlying disease-causing mechanisms of PWS remain widely unresolved and existing mouse models do not fully capture the entire spectrum of the human PWS disorder, continuous improvements of genetically engineered mouse models have proven to be very powerful and valuable tools in PWS research.

Prader-Willi syndrome (PWS)
Snord116
U-Ube3a-AS
IPW-A
116HG
mouse models
Magel2
PWS imprinting center (IC)
non-coding RNAs
Snord115
5-Ht2c serotonin receptor
Necdin
Mkrn3

1. Prader-Willi Syndrome

Prader-Willi syndrome (PWS; MIM#176270, https://www.omim.org/entry/176270, accessed on 20 March 2021) is a rare, neurodevelopmental, multifactorial genetic disorder resulting from the deletion or silencing of imprinted genes on paternally inherited chromosome 15q11–q13 ^[1]^[2]^[3]. PWS is chiefly caused by a large de novo deletion on chromosome 15q11–q13 (~60–70% of cases) (Figure 1A,B(1.,2.)). Approximately 25–35% of cases are caused by maternal uniparental disomy (i.e., two copies of maternal chromosomes UPD15) ^[4]^[5]. Less than 5% of PWS patients display defects of the genomic imprinting center (IC) and cases with sporadic chromosomal rearrangements or translocations were rarely identified ^[5]^[6]^[7].

The complex symptomology of PWS is divided into two main and phenotypically opposing stages. The onset of the first stage takes place during the last trimester of pregnancy and proceeds into infancy until around the ninth month. It is characterized by decreased movement and reduced fetal growth in utero, neonatal hypotonia, feeding difficulties and postnatal failure to thrive. This is followed by a transitional phase lasting about five to eight years with comparatively normal weight gain. The second and final stage begins around age eight and extends into adulthood ^[4]^[8]. This stage is dominated by hyperphagia and a general lack of satiety; if uncontrolled, significant weight gain ensues transitioning into morbid obesity accompanied by all associated comorbidity risks. PWS patients suffer from general and continued developmental delay, short statue, small extremities and decreased muscle mass. They are frequently affected by respiratory malfunction symptoms, sleep disorders, hypogonadism, mild mental deficiency, and disruptions of their endocrine axis. Individuals display behavioral abnormalities including temper tantrums, obsessive compulsion and skin picking ^[4]^[9]^[10]^[11]. PWS is a complex disease, and symptoms vary considerably between patients, depending on the size of the chromosomal deletion ^[2]^[12]^[13]. Its prevalence ranges from 1 in 15,000—30,000 births with no observed difference between sexes or ethnicities ^[1]^[14]^[15]^[16]^[17]. PWS has a severe impact on the health and life expectancy of affected individuals, leading to a mortality of about 3% per year (approximately three times higher than that of the normal population). Main causes of death are related to respiratory failure, cardiovascular arrest, gastrointestinal blockage as well as infections, pulmonary embolisms and choking ^[18]^[19]^[20]. Therapeutic interventions focus mainly on infant feeding assistance, growth hormone replacement and endocrine dysfunction compensation as well as the treatment of various comorbidities arising from obesity ^[21]^[22]^[23]^[24]. After more than six decades of research since PWS was first described in 1956, a causative therapy does not exist (MIM#176270, https://www.omim.org/entry/176270, accessed on 20 March 2021).

2. The Prader-Willi Syndrome Locus in Mice and Men

Genomic imprinting is an epigenetic process, which via DNA and histone methylation restricts the expression of affected genes in a parent-of-origin specific manner. From the perspective of genome encoded function, the corresponding genes represent a haploid genotype. Loss of the remaining active allele results in expression defects. Historically, PWS was the first identified and characterized disease caused by an imprinting defect and/or uniparental maternal disomy ^[25]^[26]. The PWS genomic region harbors protein coding and non-protein coding genes as well as several regulatory elements that modulate imprinting and gene expression (Figure 1). The genomic structure of the PWS locus is highly conserved in mammals, with the murine PWS region on chromosome 7C being almost identical to that of human on chromosome 15. With the exception of the protein-coding gene Frat3, which is present only in mice, and reversely for rodents, no homolog to human NPAP1 (C15ORF2) and non-protein coding SNORD108 or SNORD109A-B genes could be identified (Figure 1) ^[27]^[28]^[29]^[30]^[31]^[32]. The conservation of gene organization and imprinting pattern between mice and humans implies similar physiological functions. Therefore, genetically modified mice can represent appropriate models and tools for the investigation of this disease ^[33].

Figure 1. Organization of human and mouse PWS loci, deletions in human and PWS mouse models are indicated. (A) Schematic representation of the human PWS locus on chromosome 15q11-q13. Blue rectangles denote paternally imprinted protein coding genes. Thin ovals show snoRNA gene locations; the imprinting center (IC) is denoted by a horizontal oval. Thin rectangles above the midline depict non-protein coding exons. SNORD116 and IPW-A exons are displayed in red and further highlighted by a grey rectangle. Arrows indicate promoters and the direction of transcription. The long arrow on top shows the putative U-UBE3A antisense transcript harboring the SNORD116 and SNORD115 clusters. Centromere and telomere regions are indicated as cen and tel. (B) Schematic representation of PWS chromosomal deletions. Lines 1 and 2 indicate the common 5–6 Mb PWS deletion ^[2]. Lines 3–8 represent the characterized PWS cases with microdeletion in the Snord116 array. Line 3.—^[34], 4.—^[35], 5.—^[36], 6.—^[37], 7.—^[38], 8.—^[39] (C) Schematic representation of the mouse PWS-locus on chromosome 7qC (symbols as above). (D) Schematic representation of available mouse models in PWS research. (1.) The largest chromosomal deletion that eliminates the PWS/AS region and a large portion of non-imprinted genes ^[40]. (2.) Deletion of the mouse PWS-locus span from the Snurf/Snrpn to Ube3a genes ^[41]. (3.) Deletion of the PWS critical region (~300 kb) (PWScr) comprising of Snord116 and IPW-A gene arrays ^[42]. (4.) The Snord116del mouse model eliminating a larger ~350 kb PWScr genomic region ^[43]. Note, that the genomic assembly of PWScr is not completed, a gap of ~50 kb inside the Snord116 cluster might increase the snoRNA gene copy number and overall size of deletion (UCSC, GRCm39/mm39 chr7:59457067- 59507068). (5.) Deletion of the Snord115 gene cluster ^[44] (6.–11.) Deletions within the Snurf/Snrpn and PWS IC center (Details in Figure 2). (6.) 35 kb deletion of IC center and Snurf/Snrpn exons 1–6 ^[45]. (7.) Deletion of Snurf/Snrpn exon 6 including parts of exons 5 and 7 ^[45]. (8.) Deletion of Snurf/Snprn exon 2 ^[41]. (9.–11.) Elimination of Snurf/Snrpn exon 1 and upstream genomic region: 0.9 kb (8), 4.8 kb (9) and 6 kb (10) deletions, respectively ^[46]^[47]. (12.–15.) Deletion of protein coding genes within the PWS-locus: (12.) Ndn ^[48]^[49]^[50]^[51]; (13.) Magel2 ^[52]^[53]; (14.) Mkrn3 ^[54]; (15.) Frat3 ^[30].

3. PWS Uniparental Disomy (UPD) Murine Models

Maternal uniparental disomy (UPD) of chromosome 15 is the second most common genetic abnormality associated with PWS and is responsible for approximately 35% of cases ^[5]. Mice with maternal uniparental disomy of the central region on chromosome 7 constituted the first PWS genetic model ^[55]. It was generated by crossbreeding animals with X-autosomal translocations of the respective region ^[55]. Newborn pups exhibited weak suckling activity, failure to thrive and ultimately died within two to eight days following birth. No expression of Snrpn/Snurf gene was detectable in the brain of mutant pups, suggesting an imprinting defect ^[55].

This very first model underlined the importance of the paternal allele in the pathogenesis of PWS in mice and defined future efforts to identify the PWS critical genomic region (Table 1).

Table 1. PWS mouse models and involved genes.

Gene(s) of Interest.	Name, Aliases	Phenotype	References
all (UPD Chr 7)	T(7;18)50H/+ (JAX001816, https://www.jax.org/strain/001816, accessed on 20 March 2021)	postnatal lethality (100%) growth retardation	^[55] *
all (6.8 Mb deletion)	PWS^∆LMP2A Tg^PWS/AS(del) Del(7Herc2-Mkrn3)13FRdni/+	fetal growth retardation postnatal growth retardation neonatal lethality (100%) reduced movement irregular respiratory rate hypoglycemia pancreatic apoptosis insulin ↓, glucagon ↓ corticosterone ↑, ghrelin ↑	^[40]* ^[56]^[57]^[58]
Frat3	Frat3^lacZ Peg12^tm1Brn	none	^[30] *
Mkrn3	Mkrn3^m+/p−	lower weight from P45 earlier onset of puberty GnRH1 ↑	^[54] *
Magel2	Magel2^m+/p− Magel2 KO C57BL/6-Magel2^tm1Stw/J (JAX009062, https://www.jax.org/strain/009062, accessed on 20 March 2021)	116HG expression ↓ postnatal lethality (~10%) reduced weight until P28 body fat ↑ lean mass ↓ bone mineral density ↓ impaired glucose homeostasis impaired cholesterol homeostasis insulin resistance leptin resistance dopamine ↓, serotonin ↓ adiponectin ↑ corticosterones ↑ oxytocin ↓ different feeding behavior less active anxiety impaired social behavior delayed onset of puberty progressive infertility	^[53] * ^[59]^[60]^[61]^[62]^[63]^[64]^[65]^[66]^[67]^[68]^[69]^[70]^[71]^[72]
Magel2	Magel2^m+/p− Magel2^tm1.1Mus	postnatal lethality (~50%) weak suckling oxytocin ↓, orexin-A ↓ abnormal social behavior impaired learning ability	^[52] * ^[73]
Magel2 (overexpression of truncated protein)	CAG-trMagel2	neonatal lethality (100%) small body size, poor suckling	^[74] *
Necdin	Ndn^m+/p− Ndn^tm1Alb	none	^[51] *
Necdin	Ndn^tm2Stw B6.129S1(Cg)-Ndn^tm2Stw/J (JAX009089, https://www.jax.org/strain/009089, accessed on 20 March 2021)	postnatal lethality (80–95% C57BL/6 and 25% FVB) respiratory distress	^[48]* ^[75]^[76]
Necdin	Ndn^m+/p− B6.129S2-Ndn^tm1.1Mus	postnatal lethality (21–31%) respiratory distress oxytocin ↓ serotonin ↓	^[50] * ^[77]^[78]
Necdin	Ndn^m+/p− Ndn^tm1Ky	respiratory abnormalities DRG neuron apoptosis ↑ pain sensitivity ↓ noradrenergic excitability ↓	^[49] * ^[79]
Necdin	Ndn^m+/p− Necdin KO necdin ^m+/p−	unstable circadian rhythm	^[80] *
Snurf/Snrpn Snord116 IPW Snord115 Ube3a	Snrpn-Ube3a deletion Del(7Ube3a-Snrpn)1Alb	neonatal lethality (80%) growth retardation hypotonia	^[41] *
all (IC deletion)	PWS-IC^∆35kb Snrpn^tm2Cbr ∆PWS-IC PWS-IC^del PWS-IC^del35kb B6.129-Snrpn^tm2Cbr/J (JAX012443, https://www.jax.org/strain/012443, accessed on 20 March 2021)	neonatal lethality (40–90% depending on background) growth retardation hypotonia decreased locomotive ability abnormal behavior ghrelin ↑ increased food consumption food-seeking behavior ↑	^[45] * ^[81]^[82]^[83]^[84]^[85]^[86]
all (IC deletion)	PWS-IC^{m+/p del4.8kb} PWS-IC^∆4.8 Snrpn^tm2Alb	neonatal lethality (40%) growth retardation	^[46] *
all, except Snrpn, Snord64, 116, 115 (IC deletion)	PWS-IC^Hs Snrpn^tm1Kaj	neonatal lethality (47% C57BL/6J and 16% 129S1/Sv) growth retardation feeding difficulties	^[87] *
all (IC deletion)	PWS-IC^m+/p∆6kb PWS-IC^∆6kb B6.129S1-Snrpn^tm2.1Kaj/J (JAX018395, https://www.jax.org/strain/018395, accessed on 20 March 2021)	neonatal lethality (100%) growth retardation feeding difficulties	^[47] *
Snord116/IPW	PWScr^m+/p− Del(7Ipw-Snord116)1Jbro (distributed by TRAM Münster)	neonatal lethality (15%) growth retardation pOx ↑, Peg3 ↑ decreased gray-matter volume altered sleep profile altered body temperature	^[42] * ^[88]^[89]
Snord116/IPW	Snord116del Snord116^tm1Uta Snord116^+/−P B6(Cg)-Snord116^tm1.1Uta/J (JAX008149, https://www.jax.org/strain/008149, accessed on 20 March 2021)	growth retardation Igf1 ↓ ghrelin ↓ impaired pancreatic development altered diurnal methylation increased anxiety altered respiratory exchange rate resistant to obesity	^[43] * ^[90]^[91]^[92]^[93]^[94]
Snord116/IPW (homozygous)	Snord116^m−/p− Snord116^−/−	growth retardation fat mass ↓ increased food consumption altered diurnal activity profile resistant to obesity altered hypothalamic signaling	^[95] *
Snord116/IPW (only Npy⁺ Neurons)	Snord116^lox/lox/NPY^cre/+ (JAX008118, https://www.jax.org/strain/008118, accessed on 20 March 2021)	growth retardation fat mass ↓ increased food consumption altered diurnal activity profile altered hypothalamic signaling	^[95] *
Snord116/IPW (adult-onset)	Snord116 deletion	reduced food consumption insulin resistance	^[96]*
Snord116/IPW (adult-onset)	AAV-Snord116del^m^+/p− Snord116^flAAV-Cre	increased food consumption bodyweight ↑ bodyfat percentage ↑	^[91] *
Snord115	Snord115-deficient	brown adipose tissue ↑ modest alterations in 5-Htr2cr mRNA A-to-I editing	^[44] *
Snord116 (single copy transgene)		no effect on phenotype	^[43]*
Snord116 (transgene 2 mouse, 1 rat copies)	PWScr^m+/p−TgSnord116	no effect on phenotype	^[97] *
Snord116 (transgene 27 copies)		no effect on phenotype	^[98] *
all (biallelic IC deletion)	PWS-IC^{m∆4.8kB/p∆4.8kB} PWS-IC^{m∆4.8kB/p∆S-U}	rescue of postnatal lethality rescue of growth retardation	^[99]
Snord116/IPW (maternal IC deletion)	PWScr^{m5′LoxP/p−} (distributed by TRAM Münster)	Rescue of growth retardation in adult mice alterations in 5-Htr2cr mRNA A-to-I editing in the choroid plexus.	^[97]*
Snord116 (AAV-mediated)	Snord116del^m−/p−AAV-Snord116	energy expenditure ↑ rate of weight gain ↓	^[100] *

^{Original publications are marked by *, up- and downregulation of physiological parameters is represented by arrows (}^↑^and^↓)^.

4. PWS Large Chromosomal Deletion Models

In humans, large deletions on paternal chromosome 15q11.2-q13 were detected in more than 60% of diagnosed PWS cases—indicating that this is the most common underlying cause of the disease ^[5].

A mouse model with a deletion of the entire PWS region was generated more than two decades ago by microinjecting a fragment of an Epstein-Barr Virus Latent Membrane Protein 2A (LMP2A) vector into mouse zygotes (B6×SJL) F1 ^[40]. The resulting transgene contained a 6.8 Mb long array of ~80 repeated LMP2A copies that replaced all imprinted genes in the PWS region (Figure 1C,D; Table 1) [56]. For over four generations, the resulting transgenic PWS^∆LMP2A (TgPWS) mice were bred with C57Bl/6 and subsequently with CD1 wild-type mice for the same number of generations. Finally, one stable viable transgenic mouse line derived from a single founder was established.

For TgPWS mice with a maternally inherited modified chromosome, no phenotypic abnormalities were observed. This is in stark contrast to paternal inheritance of the modified locus, which led to failure to thrive with fetal and neonatal growth retardation, reduced movement and irregular respiratory rates. Expression of all imprinted genes from the PWS locus was abolished and mice eventually died within one week of birth due to severe hypoglycaemia ^[57]. Deregulation of the hepatic Igf (Insulin growth factor) axis and increased concentrations of corticosterone and ghrelin were reported for mutant mice. TgPWS mice also displayed elevated levels of pancreatic apoptosis; this, in turn led to reduced α- and β-cell masses and lowered levels of pancreatic islet hormones (i.e., insulin and glucagon) ^[58]. The comprehensive analysis of this mouse model with a large chromosomal deletion in the PWS-locus convincingly demonstrated that the elimination of imprinted genes causes a large spectrum of PWS-related abnormalities associated within the early postnatal period.

In contrast to human, the elimination of all genes within the PWS-locus resulted in early postnatal lethality in mice, which makes it almost impossible to use this model in the detailed investigations of the complete spectrum of PWS pathogenesis. Undoubtably, however, this mouse model confirmed that these human and mouse loci are functionally similar, which justified the utilization of genetically engineered mouse models to examine PWS-related genes in order to advance our understanding of the human syndrome.

5. Frat3

The murine Peg12/Frat3 gene (paternally expressed gene 12/frequently rearranged in advanced T-cell lymphomas 3) has no orthologue in the human PWS locus. The single CDS (Coding Sequence) exon encodes a 283 amino acid long protein, which is implicated in canonical Wnt signaling via binding to GSK-3β ^[101]^[102]. A knockout mouse model was generated in the 129/Ola background; most of the Frat3 coding sequence, i.e., including the start codon, was replaced with a lacZ-reporter gene cassette, thereby leaving its original promoter intact. Homozygous Frat3^lacZ mice lacked any obvious phenotype (Table 1) ^[30]. Moreover, molecular analysis of Frat-deficient mice revealed that it is not an essential component of the canonical Wnt pathway in mammals, and Frat3 is not involved in the PWS phenotype in mouse models ^[30].

6. Mkrn3

Intronless Mkrn3 (makorin RING-finger protein 3 [formally Zfp127]) encodes a putative E3 ubiquitin ligase of 544 amino acids (Figure 1); it inhibits the hypothalamic–pituitary–gonadal axis, thereby modulating the onset of puberty in mammals ^[103].

Mkrn3 knockout mice were generated on the C57BL/6 wild-type background via the introduction of an engineered 2 bp frameshift deletion at position 275–276 of the ORF (Open Reading Frame) in the single CDS exon of the gene (Table 1) ^[54]. Mating of Mkrn3^m+/p− males with WT (wild-type) females yielded offspring in the expected Mendelian ratio. Compared to their respective WT littermates of the same sex and age, Mkrn3^m+/p− male mice were noticeable lighter between postnatal day P15 to P60. The corresponding weight gain for female Mkrn3^m+/p− mice proceeded biphasically; KO (knockout) mice were heavier between day P15 to P40, but gained less weight compared to age-matched controls from day P45 to P60. Another effect of the Mkrn3 knockout was the earlier onset of puberty in both sexes, induced by an increased production of hypothalamic GnRH1 (gonadotropin-releasing hormone).

MKRN3 is an unlikely contributor to the key symptoms of PWS in humans ^[104]. However, these findings advanced our understanding of general regulatory mechanisms of the pubertal process and putative molecular defects causing PWS-related hypogonadism. Moreover, the genetically engineered Mkrn3^m+/p− mouse model served as a useful tool to investigate the molecular mechanism underlying human central precocious puberty (CPP) syndrome.

7. Magel2

MAGEL2 (Melanoma Antigen-subfamily like 2) is another paternally imprinted intronless gene, within the PWS locus (Figure 1) ^[64]^[72]^[105]. The human gene encodes a protein of 529-amino acids (525 amino acids in mouse) that displays about 51% sequence similarity to NECDIN, and functions as an E3 ubiquitin ligase enhancer involved in retromer endosomal protein trafficking ^[106]^[107]^[108]. MAGEL2 is particularly interesting, as patients with inactivated mutations of this gene develop the Schaaf-Yang syndrome (SYS; MIM#615547, https://www.omim.org/entry/615547, accessed on 20 March 2021). SYS shares many symptoms with PWS, including neonatal hypotonia, feeding difficulties, developmental delay, hypogonadism, intellectual disability, and a prevalence to autism-related disorder ^[109]^[110]^[111].

For the in vivo investigation of MAGEL2 functions, C57Bl6-derived Magel2^m+/p− mice were generated by replacing the C-terminus of the open reading frame with a lacZ reporter (Table 1) ^[53]. Although the promoter region remained intact, these mice entirely lacked Magel2-LacZ fusion protein expression ^[53]^[59]. Subsequent analysis revealed that in addition to Magel2-LacZ, the expression of the Ipw-A non-protein coding transcript was significantly reduced. The Magel2^m+/p− neonates displayed a postnatal lethality of ~10%, failure to thrive and growth retardation, resulting in a slight decrease in body weight until weaning (~P28). After weaning, mutant mice equaled the body weight of their WT littermates; however, KO mice were characterized by higher body fat percentage as well as decreased lean mass and muscle fibers. In addition, the bone mineral density was decreased ^[53]^[59]^[61]^[63]^[64]^[67]. When Magel2 KO mice were fed a standard diet for 12–14 weeks, a slight increase in body weight—compared to WT littermates—was observed ^[59]^[69]. Glucose and cholesterol homeostasis was impaired in Magel2 KO mice. In addition, signs of insulin and leptin resistance, defective responses to ghrelin stimulation, higher serum adiponectin concentrations, elevated corticosterones, a malfunctioning growth hormone axis and compromised melanocortin signaling were identified ^[59]^[62]^[64]^[65]^[66]^[112]. Changes in oleoylethanolamide signaling were also reported ^[69]. Concentrations of several neurotransmitters were lower in Magel2-null mouse brains, including those of dopamine and serotonin ^[60]^[70]. In addition, the lack of Magel2 in KO mice was accompanied by reduced levels of several neuropeptides, i.e., oxytocin and orexins. Furthermore, the expression of regulatory proteins that participate in processing and exocytosis of neuropeptides via secretory granules was compromised ^[53]^[71]^[72]. Magel2 null mice also revealed higher levels of mTOR and its downstream signaling targets in the hypothalamus ^[68]. The mutant mice displayed different feeding behavior, most notably an increased portion size and time per meal after a 24 h fast ^[69]. Magel2^m+/p− mice were on average less active, both in familiar and novel environments ^[53]^[61]. They exhibited increased anxiety and impaired social behavior ^[60]^[113]. Absence of Magel2 expression reduced the reproductive fitness in both sexes, results in delayed onset of puberty and irregular estrous cycles in females and decreased olfactory preference for aesthetic female odor as well as significantly reduced levels of serum testosterone in males ^[60].

An independent KO model for Magel2 was generated on a 129Sv/Pas genetic background. The entire gene promoter and approximately 75% of the CDS were deleted (Table 1). The resulting mice were subsequently backcrossed to the C57Bl6/J background ^[52]. Magel2^m+/p− neonates were not hypotonic, but sustained significantly (~50%) increased lethality, caused by weak or even absent suckling activity. Lack of Magel2 expression also impaired the production, particularly the processing from precursor to active peptide of hypothalamic neuropeptides, such as oxytocin and orexin-A. Magel2 mutants also exhibited deficiencies in social behavior and learning abilities ^[73]. The suckling initiation deficit phenotype as well as the development of behavioral abnormalities could be resolved by the injection of oxytocin in the first postnatal week ^[52]^[73].

More than half of SYS patients express a truncated version of MAGEL2, which is the result of mutation or deletion within the so-called proline-rich region upstream of the C-terminus ^[109]. Two additional mouse models were generated to analyze the functional impact of these variants. One represented a similarly truncated version of Magel2 (trMagel2) as detected in SYS patients, and a second overexpressed the transgenic Magel2 (CAG-trMagel2) N-terminal domain (amino acid residues 1–437) under the control of the CAG promoter (Table 1) ^[74]. Overexpression of the Magel2 truncated protein was highly toxic, as all CAG-trMagel positive pups died between birth and postnatal day 13. Heterozygous mice carrying the truncated trMagel2 on either the paternal Magel2^m+/p-tr or maternal Magel2^m−tr/p+ allele had no obvious phenotype. The neonatal Magel2^m+/p-tr pups were lighter than their wild-type littermates but gained weight faster until there was no detectable difference at the age of eight weeks.

Mice lacking Magel2 recapitulate a basic aspect of PWS and SYS stage I. However, none of the models developed the more severe symptoms of later stages of PWS, severe obesity combined with hyperphagia. Nevertheless, understanding the physiological function of Magel2, particularly its role in the proteolytic processing pathways of several hormones, implies an important contribution to many symptoms associated with PWS and SYS.

8. Necdin

The intronless Necdin (NDN) gene encodes a 321 amino acids long protein which is a member of the MAGE family and implicated in cell survival, maintenance of circadian rhythm ^[80], neuron migration and growth ^[114]^[115]. Neurological symptoms in PWS patients suggested a functional role of NDN in the pathophysiology of the disease ^[116]. To analyze Ndn functions in vivo, several knockout mouse models were generated. The first model was engineered in the 129SV mouse background (Table 1). The entire CDS and promoter region of Ndn was replaced by a ß-Galactosidase reporter ^[51]. The resulting mice were null for Ndn expression. Both homo- and heterozygous mutants were viable, had normal fertility, showed the same body weight development as WT mice and did not develop obesity until 10 months of age.

In-frame fusion of the first 31 Ndn codons with a lacZ reporter and replacement of the downstream CDS with the cassette was used to generate a second KO model in 129Sv derived ES (Embryonic stem) cells (Table 1). The KO strategy left the endogenous promoter intact; the resulting chimeric males were crossed with C57BL/6 WT females ^[48]. Depending on the genetic background of the female, the resulting heterozygous offspring displayed varying degrees of postnatal lethality due to respiratory problems from 80–95% for C57BL/6 and 25% for FVB to WT levels for (C57BL/6 × C3H)F1 hybrids. In most cases, the lethality was higher in male than female offspring. Respiratory distress originated from abnormalities in serotonergic modulation of the respiratory rhythm generating neurons, which are particularly sensitive to loss of Ndn expression ^[75]^[76]. The surviving mice were not associated with any detectable phenotype, did not develop obesity until 10 months of age and were fertile.

The third Ndn KO model was generated by replacing the promoter and two-thirds of the N-terminal Ndn coding sequence with the Neo cassette flanked by LoxP sites, which was subsequently removed by crossing with Cre-expressing C57Bl6/J females (Table 1) ^[50]. Heterozygous neonates displayed 21–31% lethality due to respiratory distress ^[50]^[77]. The surviving mice were fertile, exhibited normal weight development and did not become obese during an 18-month observational period. Ndn^m+/p− mice displayed a significant reduction in oxytocin-producing and luteinizing hormone-releasing hormone (LHRH)- producing neurons in hypothalamus. The Ndn null mutants had a normal circadian rhythm, normal motoric skills and showed no abnormalities in anxiety-related behavior, but were superior in spatial learning and memory tests. Notably, skin scraping was significantly increased in Ndn^m+/p− mice compared to the wild-type control. Homozygous Ndn^m−/p− offspring had an even higher postnatal lethality of 43% compared to heterozygotes, most likely due to respiratory deficiency ^[77]. Interestingly, low Ndn expression levels were detectable from the maternal allele in two Ndn^m+/p− mouse strains (C57Bl/6J and 129Sv/Pas). There was also a drastic (i.e., up to three orders of magnitude) inter-individual variability of Ndn expression between Ndn^m+/p− mice. Complete loss of Ndn expression in surviving homozygous mice altered the development and function of serotonergic neurons, resulting in central apnea and hypercapnia ^[78]. Ndn^m+/p− mice showed a significant, i.e., up to three-fold, upregulation of Slc6a4 (serotonin transporter, solute carrier family 6 member 4) expression, which results in an increase of serotonin (re-)uptake and thereby decreased extracellular serotonin to insufficient levels, ultimately causing breathing deficits.

Another model was generated by conventional gene targeting, with a 1.5 kb Pgk/NeoR cassette inserted into the Ndn gene to disrupt its coding sequence (Table 1) ^[49]. The targeting vector was electroporated into TT2 ES cells. Positive clones were injected into ICR embryos and the resulting chimeras were backcrossed to ICR wild-type mice. The heterozygous Ndn^m+/p− mice did not reveal any increased postnatal lethality, were fertile and bred in the normal Mendelian ratio. Necdin deficiency triggered apoptosis in developing mouse dorsal root ganglia at E12,5 and led to a significant reduction in total neuron number at P0. The Ndn^m+/p− also had a significantly increased tolerance to pain compared to the wild-type control at the age of two and four weeks. Five-day-old Ndn^m+/p− neonates displayed some signs of hypotonia, although there were no significant differences by the age of two weeks ^[79]. The mutant also had an impaired ventilatory response to hypercapnia at postnatal days 4 and 8. The neurons of the noradrenergic system in the locus coeruleus of Ndn^m+/p− mice are characterized by decreased spontaneous activities and showed impaired excitability.

Recently, using CRISPR/Cas9-mediated genome engineering, a Necdin deficient mouse model harboring a 1349 bp deletion within the Ndn gene was generated on a C57BL/6 background (Table 1) ^[80]. Lack of necdin protein destabilized a key component of the circadian clock and resulted in alterations of clock gene expression compared to wild-type and an unstable circadian rhythm in Ndn^m+/p− mice.

The Ndn mouse models successfully reproduced both the respiratory and sleep disorder related phenotype of PWS; therefore, they are suitable for the development of novel therapeutic approaches, as respiratory failure is the most common cause of death in infants and children diagnosed with PWS [18]. As previously noted ^[117], it is remarkable that the majority of protein coding genes in this locus were generated via retrotransposition, emphasizing once more the significance of this mechanism for the evolution of genes and entire gene loci ^[118].

9. Snurf/Snrpn

The SNURF/SNRPN (Small Nuclear Ribonucleoprotein Polypeptide N) gene encodes two different proteins from a bicistronic transcript spanning 10 exons and is highly conserved between humans and mice ^[119]. CDS exons 1–3 encode for the 71 amino acids protein Snurf (SNRPN upstream open reading frame), while CDS exons 4–10 encode for a 240 amino acids component of the SmN complex (small nuclear ribonucleoprotein complex) ^[120]. The SNURF/SNRPN bicistronic transcript is highly expressed in the brain and heart in both humans and mice. SNURF localizes to the nucleus but its function is still unknown. SmN plays a role in pre-mRNA processing and possibly alternative splicing, regulating the development of the spine and cerebral cortex in mice ^[121]^[122]^[123]. For numerous patients diagnosed with PWS, deletions of the SNURF/SNRPN gene were detectable, suggesting that its product(s) might contribute to the pathology of the disease ^[124]^[125]^[126]. For the analysis of Snurf/Snrpn functions, seven different genetically modified mouse models were generated (Figure 2). Three of them contained small deletions of the Snurf/Snrpn protein coding region, eliminating CDS exon 2, exons 5–7 and exon 1, respectively (Figure 2B–D). A fourth model harbored a long deletion eliminating Snurf/Snrpn exon 2 up to the Ube3a gene region (Figure 2A) ^[41]^[45]. Regardless of the actual mouse genetic background, i.e., C57BL/6 or 129/SvEv–C57BL/6J hybrids, the offspring with paternally inherited Snurf/Snrpn small deletions (Figure 2B–D) were indistinguishable from wild-type littermates. They exhibited a normal imprinting pattern, were fertile and displayed no obvious phenotypic abnormalities ^[41]^[45]

Figure 2. Schematic representation of genetically engineered mouse models harboring deletions within Snurf/Snrpn and PWS IC center (drawings are not to scale). Green and thin blue rectangles denote Ube3a and Snurf/Snrpn CDS exons, respectively. The red rectangles indicate generated genomic deletions. Thin black rectangles show location of U-exons; the imprinting center (IC) is denoted by a horizontal oval. (A). Large deletion of the genomic region between Snurf/Snrpn exon 2 and Ube3a exon 2. ^[41]. (B). Inactivation of the Snurf ORF by deleting the 6 kb region including Snurf/Snrpn exon 2 ^[41]. (C). Intragenic deletion of 1.6 kb within Snurf/Snrpn including exon 6 and parts of exons 5 and 7 disrupting the Snrpn ORF ^[45]. (D). Small 0.9 kb deletion of the major Snurf/Snrpn promoter together with first CDS exon ^[46]. (E). The PWS IC deletion, spanning 35 kb (originally described as 42 kb) including Snurf/Snrpn exons 1–6 ^[45]. (F). Deletion of 4.8 kb (later revealed to be 5.07 kb in size) genomic region, including Snurf/Snrpn exon 1 and the distal part of the PWS IC ^[46]. (G). The 6 kb deletion comprising PWS IC and Snurf/Snrpn exon 1 ^[47].

Different results were obtained in a mouse model with a deletion from Snrpn exon 2 to Ube3a (Figure 1D and Figure 2A; Table 1) ^[41]. Mice homozygous for this long deletion did not survive past E20. Heterozygotes with the long deletion on the paternal allele were weak, hypotonic and had weak suckling activity. They were underweight at birth and showed severe growth retardation compared to WT littermates; only about 20% of the mutant pups survived until weaning. The surviving knockout mice were fertile, had about 2/3 of the bodyweight of age-matched WT animals, and did not develop obesity within a 14-month observational period ^[41]. These data raised doubts with regards to the functional significance of the SNURF/SNRPN gene as the primary cause of PWS and underlined the importance of the PWS critical region, which at the time, had not been identified.

10. PWS Imprinting Center

In the late nineties, a 35 kb deletion (originally reported as 42 kb) encompassing SNURF/SNRPN CDS exons 1–6 and its 16 kb upstream region was generated in C57BL/6 mice by replacing the corresponding sequence with a Pgk-Neo-polyA cassette (Figure 1D and Figure 2E; Table 1)^[45]. This deletion (PWS-IC^∆^35kb) resulted in a complete imprinting defect and thus abolished expression of all imprinted genes in the locus. PWS-IC^∆^35kb neonates had decreased body weight and hypotonia at birth, resulting in poor suckling and low blood glucose levels. Ultimately, the offspring died within the first week due to feeding difficulties. However, this fully penetrant neonatal lethality was highly dependent on the genetic background. C57BL/6 males carrying the maternal PWS-IC^∆^35kb allele produced viable offspring (survival rates between 10%–60%) with female mice of FVB/NJ, C3H/HeJ, 129S1/Sv and BALB/cJ genetic background, but not with C57BL/6J or DBA/2J animals ^[81]. Viable pups, especially after separation from WT siblings, grew into adulthood and were at all times smaller than WT controls. PWS-IC^∆^35kb had normal fertility and did not develop obesity until the end of the 15-week observational period. The mouse background-dependent survival was putatively independent of residual expression of genes from the paternal chromosome or leakage from the maternal chromosome, since the detected expression levels did not correlate with survival rate ^[81]. The most likely explanation of the observed differences is strain specific gene-modifiers affecting survival ^[81]. PWS-IC^m+/p∆35kb mice generated by crossing PWS-IC^∆^35kb C57BL/6J males to CD-1 females exhibited less locomotive activity and impaired attentional functions, but normal anxiety levels compared to WT ^[82]. Furthermore, PWS-IC^m+/p∆35kb mice showed increased impulsivity and locomotor activity when motivated by food reward ^[83]. There were no detectable differences in whole tissue monoamine levels or expression and splicing of 5Ht2cr (see below). The PWS-IC^m^+/p∆35kb mice also underperformed in a stop-signal reaction time task compared to WT mice suggesting increased impulsivity. This effect could be ameliorated with the selective 5Ht2cr agonist WAY163909 ^[85]. Compared to the wild-type control, circulating ghrelin levels were elevated up to threefold in PWS-IC^m+/p∆35kb mice. Mutants were also characterized by significantly higher food consumption, both with ad libitum access and after an overnight fast ^[84]. In contrast to wild-type mice, PWS-IC^m+/p∆35kb mice reacted with apathy towards non-caloric sweetener and showed a preference for food of high caloric value. Interestingly, PWS-IC^m+/p∆35kb mice performed better in a maze-learning test than wild-type mice when combined with food reward. These findings might suggest increased motivation due to stronger food-seeking behavior ^[86].

To narrow down the critical size of the imprinting center, additional in vivo models were generated by targeting the DNA methylation region (DMR) located upstream of the Snurf/Snrpn CDS exons. Two models encompassing deletions of 0.9 kb and 4.8 kb were generated (Figure 2D,F; Table 1). The latter was later revealed to be 5.07 kb ^[47]; but, designated as PWS-IC^m+/p∆4.8kb model in the literature. Notably, the larger deletion eliminated almost the entire methylation region (~2.7 kb), leaving only a small part intact ^[46]. Heterozygous mice harboring the small deletion (0.9 kb) displayed a regular imprinting pattern, were phenotypically unremarkable, fertile and had no weight abnormalities compared to WT mice. The paternal inheritance of the 4.8 kb deletion, on the other hand, resulted in an approximate 40% postnatal lethality. The growth of surviving PWS-IC^m+/p∆4.8kb mice was retarded, amounting to a 30% decrease in size and bodyweight. However, the mutant mice harboring the paternal deletion were fertile. Notably, the 4.8 kb deletion resulted in a partial imprinting defect, therefore the PWS-IC^m+/p∆4.8kb mice displayed low expression levels of PWS-locus encoded genes.

To define the imprinting center of the mouse PWS-locus, a further model harboring a 6 kb deletion was generated, eliminating about 3.7 kb upstream from Snurf/Snrpn exon 1 (Figure 2G; Table 1) ^[47]. The 3′ end of this 6 kb deletion was identical to that of the previously mentioned 4.8 kb deletion. The PWS-IC^m+/p∆6kb offspring containing the deletion on the paternally inherited chromosome were significantly smaller and weaker than their WT littermates. They often lacked milk spots and did not survive past postnatal day 7, with most of the pups dying within 48 h after birth. PWS-IC^m+/p∆6kb mice displayed no detectable expression of PWS genes from the paternal allele, indicating that functional elements enabling PWS-IC activity were present within the deleted interval ^[47].

For the investigation of the human PWS imprinting region, a knock-in transgenic mouse model was generated by replacing the mouse 6 kb PWS-IC with a 6.9 kb fragment of the entire human PWS-IC region (Table 1) ^[47]^[87]. Knock-in mice harboring human PWS-IC^Hs acquired maternal DNA methylation patterns. Paternal inheritance of the PWS-IC^Hsled to a neonatal lethality of 47% in the second generation with a C57BL/6J background and 16% postnatal lethality with a 129S1/Sv background. The PWS-IC^Hs mutant pups were significantly smaller, had difficulties feeding and displayed considerable growth retardation, which was accompanied by a 50% reduced bodyweight; the effect persisted into adulthood. Paternal inheritance of the PWS-IC^Hs resulted in almost complete absence of the Ndn, Mkrn3, Magel2 and Frat3 gene products, but expression of U-Ube3a-As derived non-protein coding RNAs, including Snord64, Snord116, Snord115 and Ube3a-As remained unaltered ^[87].

The data implied that the mechanism to acquire silencing is conserved between humans and mice, but the maintenance and regulation of the silenced state is different. This also might explain the differences in the regulation of tissue-specific expression of PWS encoded genes between both species ^[127]. In any event, the analysis conducted with these mouse models defined the PWS-locus imprinting center in mice and revealed that the imprinting effect is similar in mice and men.

11. Snord116 Gene Cluster

Imprinted SNORD small nucleolar RNAs (snoRNAs) within the PWS-locus were originally identified two decades ago ^[128]. Based on the presence of conserved C and D sequence motifs, these snoRNAs were assigned to the subclass of 2′-O-methylation guide C/D box snoRNAs. However, due to the apparent lack of any significant complementarities to classical snoRNA target molecules (rRNAs, snRNA) they are referred to as “orphan” snoRNAs ^[129]. The human PWS region harbors seven SNORD genes and families: SNORD107, SNORD64, SNORD108, SNORD109A, SNORD116, SNORD115 and SNORD109B. The corresponding mouse locus contains the orthologous genes Snord107, Snord64, Snord116 and Snord115. Most snoRNAs from the PWS-locus are processed from introns of a long primary non-protein coding U-UBE3A-AS transcript (U-Ube3a-AS in mouse) (Figure 1). Both the human and murine genes are paternally imprinted. In human, SNORD116 and SNORD115 genes represent tandemly repeated arrays comprised of 29 and 48 copies, respectively ^[129]. SNORD116 copies are located within introns flanked by the repetitive IPW-A exons of the U-UBE3A-AS transcript (Figure 1A). SNORD115 copies are embedded between repetitive IPW-G exons (Figure 1A). In mice, 66 copies of Snord116 are distributed in the introns of 67 Ipw-A exons (Figure 1C). However, due to an assembly gap of approximately 50 kb inside the mouse Snord116 region, the exact number of repeats is yet to be determined. Although SNORD116 displays a high degree of sequence similarity between different mammalian species ^[130], conventional targets on rRNAs cannot be identified ^[128]^[129]. In rodents, expression of the PWS locus encoded snoRNAs is restricted to neurons, while in humans they are most abundant in brain but also expressed in other tissues ^[127].

11.1. The First Mouse Model Harboring the Deletion of the PWS Critical Region (PWScr^m+/p−)

Analysis of the aforementioned mouse models that abolished the expression of single or multiple genes predicted PWS critical region (PWScr) within the Snord116 gene cluster ^[131]. To investigate the putative contribution of Snord116 to the PWS phenotype in vivo, two mouse models were generated. The first model harbored a ~300 kb genomic deletion (UCSC, GRCm39/mm39 chr7:59,277,590-59,580,881) of the Snord116 and Ipw-A gene arrays and was designated as PWScr deletion model (Figure 1 C,D; Table 1) ^[42]. PWScr^m+/p− pups displayed significant growth retardation starting from postnatal day 5 lasting into adulthood, i.e., up to one year of monitoring. Growth retardation was observed independent of the following genetic backgrounds: 129SV × C57BL/6 (>85% C57BL/6 contribution), 129SV × C57BL/6 × FVB/N (~50% FVB/N contribution) as well as 129SV × C57BL/6 × BALB/c (~50% BALB/c contribution). A slight increase in postnatal lethality of about 15% as well as between P1 and P22 was observed for the 129SV × C57BL/6 genetic background. Because no difference in bodyweight was detected for embryos at E12.5, E15.5 or E18.5, the failure to thrive was most likely caused by reduced feeding capabilities. PWScr^m+/p− mice were fertile, bred in the expected Mendelian ratio and did not become obese at any point in time ^[42]. Expression of other genes in the PWS locus remained unaffected, except for a small decrease of the Snord115 and Ipw-G exon expression ^[97].

In addition, magnetic resonance imaging revealed a decrease of grey-matter volume in the ventral hippocampus and septum areas of PWScr^m+/p− mice ^[89]. Orexin and melanin concentrating hormone systems in the lateral hippocampus were impaired in mutant mice, as the deletion of Snord116 gene cluster causes a 60% reduction in orexin expressing neurons ^[88]. Consequently, expression of pOx (prepro-orexin) and Peg3 (paternally imprinted gene 3) were significantly upregulated in PWScr^m+/p− ^[88]. The analysis of RNA-seq data led to the identification of >4000 differentially regulated genes in the hypothalamus of PWScr^m+/p− mice compared to wild-type controls ^[88]. Among the upregulated genes were those related to neurotransmitter transport, synaptic organization and cytokine production pathways ^[88]. PWScr^m+/p− mice also exhibited dysregulated “rapid eye movement” (REM) sleep, reduced peripheral thermoregulatory response, as well as an increase of peripheral body temperature compared to wild-type littermates during the light phase of the day. Those observations suggested that in addition to Ndn, PWScr derived non-protein coding RNAs also contribute to the regulation of sleep physiological measures in PWS ^[88].

11.2. The Second Mouse Model Harboring the Deletion of the PWS Critical Region (Snord116del)

The second mouse model featured an ~350 kb deletion of the Snord116 gene cluster (UCSC, GRCm39/mm39 chr7:59,275,265-59,624,663—based on the location of genotyping primers). This eliminates an ~50 kb longer upstream region as opposed to the PWScr^m+/p− model (Figure 1C,D; Table 1)^[43]. Gene targeting was performed by homologous recombination in BRUCE4 ES cells, thereby introducing LoxP sites flanking the Snord116 gene array. Selected ES cell clones were injected into C57Bl/6J-Tyr^c−2J/J albino blastocysts. Heterozygous offspring derived from the chimeras were mated with a transgenic C57BL/6J strain expressing Cre-recombinase. In a second experimental approach, targeted ES cells were transfected with a Cre expressing vector prior to blastocyst injection ^[43].

Offspring from both lines exhibited a similar phenotype and transmitted the paternal deletion through the germline. Although the entire cluster consisting of Ipw-A exons and Snord116 genes was paternally deleted, the mouse model was named Snord116del. The expression of other genes in the PWS-locus remained unaffected by the deletion, except for the neighboring genes flanking the deletion. Thus, an approximate 35% decrease and a 33% increase in expression of Snord107 and Snord115 genes was observed, respectively ^[43]. Notably, this is in contrast to a slight decrease of the Snord115 gene expression in PWScr^m+/p− mice compared to WT littermates [97]. Similarly, to the PWScr^m+/p− model, newborn Snord116del^m+/p− pups P0 harboring the paternally inherited deletion were indistinguishable from WT littermates. Growth retardation was detected from postnatal day 2 onwards.

In Snord116del mice, which were homozygous for the deletion (Snord116del^m−/p−), reduced bone and fat mass relative to their bodyweight accompanied by an increase in lean mass was reported ^[95]. Snord116del mice were fertile and bred normally, although the female sexual maturation was delayed. Interestingly, postnatal lethality was not reported for this Snord116del model and mice were healthy during the 18-month observation. It was hypothesized that the failure to thrive was due to hypotonia and insufficient suckling, but neither hypotonia nor empty stomachs were observed in Snord116del pups. However, the livers and stomachs of Snord116del pups weighed less at P5 and P13 than those of their WT littermates, which might indicate a decreased rather than absent milk intake. An overall decreased stomach weight was also observed in the PWScr^m+/p− model, but the effect was not statistically significant when the reduced bodyweight of the animals was taken into account (Skryabin et al., unpublished)^[42]. Igf1 levels were significantly lower in mice lacking Snord116 expression, although there were no detectable anomalies of the pituitary gland itself ^[43].

The onset of locomotive abilities was delayed in Snord116del mice; yet, no differences in motor abilities were detected when reflex-related tasks were tested ^[90]. Furthermore, Snord116del mice exhibited an impairment in the recognition of novel objects and the memory of object location. In addition, the mice demonstrated a tendency towards increased anxiety-related behavior.

Food consumption was normal in the paternally deleted Snord116del ^m+/p− mice, both on regular chow and high-fat diet. Indeed, the mutants were even somewhat resistant to obesity, as— compared to WT siblings—they displayed significantly lower bodyfat percentages after 4 months on a high-fat diet ^[43]. Despite these findings, initial analysis of Snord116del^m+/p− mice revealed an increase in food intake relative to their lower bodyweight, which was interpreted as hyperphagia ^[43]. Forthcoming studies revealed altered diurnal energy regulation in Snord116del mice, thereby showing decreased respiratory exchange rates (a result of increased fat oxidation as opposed to carbohydrate) during the 12-h light period ^[94]. Ghrelin levels in Snord116del with ad libitum access to food were significantly increased and comparable to the level observed in WT mice after a 24h fast, whereas insulin sensitivity was normal in mutant females but increased in males ^[94]. In late adulthood (28–34 weeks of age), increased glucose tolerance and insulin sensitivity were detected independent of Snord116del^m−/p− gender ^[95]. Snord116del^m−/p− mice exhibited ~11% and ~31% higher calories per gram of bodyweight uptake in early (12–16 weeks of age) and late adulthood (28–34 weeks of age) ^[95]. In early adulthood, Snord116del^m−/p− mice showed lower activity levels during the 12-h dark phase and increased energy expenditure during the light phase. However, in late adulthood, this profile was inverted, leading to increased activity during the dark phase ^[95]. Core body temperature was also reduced in mutant mice in early adulthood. Snord116del^m−/p− mice were partially resistant to high fat diet-induced obesity, which subsequently, did not lead to a significant increase in bodyweight compared to normal chow, although the fat mass was increased ^[95]. In stark contrast, recent analysis uncovered that paternally inherited Snord116del mice displayed no significant differences (compared to the WT controls) in the 24-h food intake of animals that had ad libitum access or those following a 24-h fast ^[91]. However, when the Snord116 cluster was specifically eliminated in the mediobasal hypothalamus of adult mice, hyperphagia leading to obesity in a subset of animals was detected ^[91].

However, when the Snord116del-based model harboring a mosaic partial deletion of the Snord116 gene cluster was investigated in adult animals, the 16% reduction of Snord116 expression did not result in any significant effect on bodyweight. In addition, no remarkable change in weight of any major tissue/organ or even the lean mass was identified ^[96]. Reduction of Snord116 expression resulted in an increase of small white adipose tissue mass; yet, food intake was reduced during ad libitum food access or after a 48-h fast ^[96]. The mosaic mice displayed an impaired glucose clearance rate and insulin resistance at 13 weeks of age ^[96]. There was no detectable difference in energy expenditure or respiratory exchange rate, only a short time delay during the transition from the light, somnolent phase to the dark, active phase.

Changes in expression profiles of selected genes were investigated in Snord116del mice by various research groups. The analysis of genes representing the leptin/melanocortin pathway revealed inconsistent results. Some approaches uncovered no altered expression profiles for Npy (neuropeptide Y), Lepr (leptin receptor), Agr (agouti-related protein), Pomc (Proopiomelanocortin), Pcsk1 (prohormone convertase 1) or its transcription activator Nhlh2(nescient helix-loop-helix 2) genes ^[91]. However, early reports demonstrated reduced expression levels of Pcsk1 and Nhlh2 genes and a shift in the ratio of active to inactive precursor forms of circulating hormones, e.g., proinsulin-insulin, preproghrelin-ghrelin, an effect which is presumably due to the impairment of the necessary processing pathway ^[93]. The same group also reported a significant increase of Npy and Agr expression in Snord116del mice after refeeding. The Snord116 deletion also leads to an impairment of pancreatic development, resulting in a reduction of pancreatic islet size and a decrease of insulin 1(Ins1) and insulin 2(Ins2) gene expression ^[92]. In addition, expression of Pdx1,Pax6 and Nkx6-1 transcription factors, which are important for pancreatic development, was downregulated in adult Snord116del mice. In the cerebellum of Snord116del at postnatal day 30, the mean cell body diameter of Purkinje neurons was reduced by 21%. In the cortex of Snord116del mice, the number of diurnal differentially methylated regions was dramatically reduced, with only 3% of regions showing the same rhythmic methylation pattern that is present in wild-type mice ^[132]. Among those genes that were epigenetically dysregulated in Snord116del mice, functional clusters regulating the circadian entrainment, AMPK (AMP-activated Protein Kinase) signaling, stem cell pluripotency, axon guidance, insulin resistance and dopaminergic synapse function were identified. Interestingly, in Snord116del mice, altered diurnal methylation of the imprinted Dlk1-Dio3 locus and upregulation of its maternally expressed genes were reported, suggesting putative “cross-talk” between two imprinted loci ^[132].

Results obtained from the Snord116 KO models are in accordance with the current leading hypothesis that the absence of SNORD116 gene clusters indeed plays a causative role in the early onset of PWS pathogenesis. SNORD116 genomic regions became a prime focus following the discovery of PWS patients harboring a rare minimal deletion of the SNORD116 gene cluster (Figure 1A) ^[34]^[35]^[36]^[37]^[38]^[39].

Despite the fact that the IPW-A exons show little sequence conservation among mammals, we cannot completely rule out functional roles of exon-derived large non-protein coding RNAs in the PWScr region. Since SNORD116 genes from this cluster are the only genes from this region that exhibit a high degree of sequence similarities between different mammals, most research is aimed at elucidating their function. However, the PWScr region, as part of a long non-protein coding U-UBE3A-AS transcript, also encodes IPW-A- exons; yet, the functional significance of SNORD116 or non-protein coding IPW-A- exons, or the roles of both in the pathogenesis of PWS are yet to be elucidated.

12. Snord115 Gene Cluster

SNORD115 is another large, imprinted gene cluster identified within the PWS locus (Figure 1). Historically, it was the first snoRNA with a presumed mRNA target. The antisense element within the snoRNA exhibits an 18 nt long evolutionarily conserved complementarity to the alternatively spliced exon Vb of the 5-HT2C serotonin receptor pre-mRNA that is also subject of posttranscriptional A-to-I editing (Figure 3). The 5-HT2C receptor is part of many complex regulatory networks that, amongst others, have been linked to obesity, feeding behavior, mental state, sleep cycles, autism, neuropsychiatric disorders (e.g., schizophrenia, depression) and neurodegenerative diseases (e.g., Parkinson, Alzheimer)^[133]^[134]. Alternative splicing of exon V of the 5-HT2C receptor pre-mRNA results in an inactive, truncated variant of the receptor. The efficacy of 5-HT2CR G-protein coupling is regulated via posttranscriptional A-to-I editing of the pre-mRNA within the exon Vb region, which generates over 32 different 5-HT2CR mRNA isoforms that collectively modulate the serotonergic signal transduction to varying degrees ^[135]^[136]. Ex vivo experiments in HEK293 or Neuro2A cells demonstrated that SNORD115 can interfere with alternative splicing of the 5-HT2C serotonin receptor pre-mRNA. However, this was only observed when the original splice site of pre-mRNA had been mutated for optimal splicing ^[137]. Studies examining the PWS-IC^m^+/p∆35kb mouse model that express barely detectable levels of Snord115, revealed conflicting results. Initially, it was suggested that the absence of Snord115 RNA did not affect alternative splicing of 5-Ht2cr pre-mRNA ^[83]. However, more recently, the same group reported increased expression of the truncated receptor isoform in the hypothalamus of PWS-IC^m^+/p∆35kb mice ^[138]. In mice, Snord115 is expressed in neurons but is entirely absent from the choroid plexus, an area where 5-Ht2cr mRNA is abundant. RNA deep sequencing analysis of choroid plexus samples from a mouse model with ectopic Snord115 expression revealed that Snord115 is not involved in the regulation of 5-Ht2cr pre-mRNA alternative splicing in vivo ^[139]. Recently, a long-awaited mouse model harboring the paternal deletion of the Snord115 gene cluster in the C57BL/6J genetic background was reported (Figure 1C,D; Table 1) ^[44]. RNA deep sequencing of different brain areas revealed that the lack of Snord115 expression does not alter alternative splicing of 5-Ht2cr pre-mRNA ^[44]. Likewise, transcriptome analysis of hypothalamus samples from PWS patients did not detect differences in 5-HT2CR pre-mRNA splicing ^[140].

Figure 3. Schematic representation of 5-Ht2cr pre-mRNA exons IV to VI and putative targeting region of Snord115 within exon Vb (drawings are not to scale). Alternative splicing site (GU) of 5-Ht2cr pre-mRNA exon Vb is indicated with bold italic letters. A-to-I editing sites A–D are denoted in red and labeled with arrows, accordingly. Snord115 C- and D-boxes are highlighted ^[128]^[139].

In addition, potential SNORD115 functions in the regulation of 5-Ht2cr pre-mRNA posttranscriptional A-to-I editing were explored. Ex vivo experiments in cell culture demonstrated that Snord115 can interfere with RNA editing if an atypically nucleolar-localized mRNA substrate is present ^[141]. The analysis of the “autistic” mouse model, which harbors a paternal duplication of the PWS-locus imprinted genes (patDp/+ mouse) and PWS-IC^m^+/p∆35kb mice reported an increase of A-to-I editing of 5-Ht2cr pre-mRNA ^[83]^[142]. However, both studies lack sufficient sequencing depth and are controversial due to differences in Snord115 expression levels (~2-fold increase in patDp/+ mice and almost no expression in PWS-IC^m^+/p∆35kb mice) [83,142]. The analysis of mouse models with ectopic expression of Snord115 in the choroid plexus suggested the formation of a double-stranded structure between Snord115 and exon Vb of 5-Ht2cr pre-mRNA, which may also be subject to ADAR (Adenosine deaminases acting on RNA)-mediated A-to-I editing, i.e., similar to the intramolecular duplex formed by exon Vb and the downstream intron of 5-Ht2cr pre-mRNA ^[139]. Consequently, analysis of 5-Ht2cr pre-mRNA revealed only a modestly reduced A-to-I editing at major sites, questioning the overall biological significance of the Snord115-5Ht2c receptor pre-mRNA interaction and its contribution to PWS pathophysiology ^[139]. A mouse model with a paternal deletion of the Snord115 gene cluster also revealed only modest alterations in 5-Htr2cr mRNA editing profiles ^[44]; moreover, differences were detected in a brain region-specific manner. The functional significance of these minor changes remains to be resolved, as mice showed no obvious phenotypic abnormalities, they bred normally, displayed normal growth patterns and energy balance on either a normal chow or high fat diet. There were no noticeable differences in social or emotional behavioral phenotypes associated with altered 5-Htr2c receptor regulation ^[44]. Therefore, a functional interaction of Snord115 with pre-mRNA or mRNA targets, should be considered fortuitous, until there is sound in vivo evidence ^[143]. This stretch of complementarity is rather testimony to the manner in which sequences of genomes evolve, namely by duplicating existing genetic material and deletions and not by out of the blue de novo generation. As a result, the sequence of genomes is much less complex than theoretically possible, alone due to the presence of at least 50% repetitive elements, e.g., in humans ^[144].

13. PWS Compensation Models

Genetically modified mouse models and the identification of PWS patients with rare small deletions helped to pinpoint the minimal PWS critical region (PWScr) to the SNORD116/IPW-A genomic region. However, an important question remained unanswered. Is the deletion of genomic DNA harboring unknown regulatory elements or is the lack of non-protein coding RNA expression causative of PWS in patients? Therefore, additional mouse models were generated, in which non-protein coding RNA(s) of PWScr was re-introduced into expression-lacking animals that exhibited a typical PWS-like phenotype. As the SNORD116 genes within the PWScr region exhibit the highest degree of sequence similarity between different mammalian species, most effort had been devoted to understanding their functions. Two Snord116 transgenic mouse lines expressing snoRNA embedded in introns of different host genes were generated (Table 1). The first model contained a single copy transgenic Snord116 within nucleolin intron 11 driven by a neural-specific enolase promoter. This transgene was crossed with a PWS knockout mouse line containing a deletion from Snrpn to Ube3a, encompassing the complete PWScr ^[142]. Expression from the transgene failed to rescue either the neonatal lethality or growth retardation of mice with the paternal inheritance of the deletion. These negative results were explained by potentially insufficient expression levels of the single copy gene compared to the highly abundant endogenous Snord116 RNA transcribed from a cluster containing over 66 repeats.

The second model (TgSnord116) was generated by expressing two copies of mouse Snord116 and one copy of rat Snord116 from the introns of an eGFP host gene [97]. Transgenic mice were crossed with a PWScr^m+/p− mouse model, resulting in PWScr^m+/p−TgSnord116 animals. Transgene expression of Snord116 did not compensate the growth retardation phenotype observed in the PWScr^m+/p− model [97]. A possible explanation could be the tissue-specific expression of the transgenic eGFP construct, which was absent in thalamus, hypothalamus, midbrain and pons of PWScr^m+/p−TgSnord116 mice [97]. Because dysregulation of the hypothalamic endocrine system is associated with PWS in humans, one would expect that absence of Snord116 expression in this tissue could contribute to growth retardation in mice ^[145]^[146]. Consequently, the important question of the functional significance of Snord116 in PWS still needed to be addressed by generating compensatory transgenic animals that express Snord116 in the same brain regions as wild-type mice.

In an attempt to achieve a sufficient expression level of transgenic Snord116 in the Snord116del^m+/p− knockout model, a transgene carrying multiple copies of Snord116 and Ipw-A exons was designed to mimic the original gene organization (Table 1) ^[98]. The transgene construct contained three complete PWScr repeat units under the control of a cytomegalovirus (CMV) promoter. Each repeat contained an intron located Snord116 copy embedded by Ipw-A exons. Pronuclear injection of fertilized oocytes with the engineered DNA construct resulted in transgenic mice putatively with head-to-tail donor DNA integration, which often occurs during knock-in or transgene generation ^[147]^[148]. The construct was integrated nine times in the genome, resulting in a total of 27 copies of Snord116 ^[98]. The insertion was identified at chromosomal region 7qE3 about 47 Mb away from the PWScr region. The resulting transgene failed to express Snord116 and Ipw-A exons on a Snord116del^m+/p− knockout background and hence, to rescue the growth retardation phenotype ^[98].

In an attempt to re-introduce Snord116 RNAs into the hypothalamus of adult Snord116del mouse models (Snord116del^m−/p−) at different ages, an AAV vector expressing a single Snord116 copy was injected into Snord116del^m−/p− male mice (Table 1) ^[100]. Apparently, no significant effects were observed, except for a slight increase in energy expenditure when compared to the vehicle-injected Snord116del^m−/p− control mice, as well as a reduced rate of weight gain. The effect of the viral Snord116 expression in knockout animals was rather low and also highly dependent on the age of treated mice and region of injection, generally favoring younger mice and those that were injected in the mid- (rather than anterior) region of the hypothalamus ^[100]. However, lack of Snord116 expression quantification from the AAV vector together with putative differences observed at various time points of virus microinjections raised questions about the application and potential efficacy of AAV mediated gene therapy for PWS patients.

An alternative strategy was to inactivate the PWS imprinting center on the maternal chromosome (Table 1). To do this, the effects of maternal transmission of the 4.8 kb IC and exon 1 Snrpn deletion were studied ^[99]. Maternal inheritance of the deletion resulted in active expression of both protein coding and non-protein coding genes in the PWS locus from the maternal allele in mice whose expression of the paternal allele was impaired due to either a short 4.8 kb deletion on the IC-center at the paternal PWS-IC^{m∆4.8kb/p∆4.8kb} allele or due to a large chromosomal deletion from Snrpn exon 2 to the Ube3a gene—PWS-IC^{m∆4.8kb/p∆S-U}. Remarkably, the maternal expression was able to rescue the prominent postnatal lethality phenotype in both the small (survival rate PWS-IC^m+/p∆S-U: 56%, PWS-IC^{m∆4.8kb/p∆S-U}: 96%) and large (PWS-IC^m+/p∆S-U: 0%, PWS-IC^{m∆4.8kb/p∆S-U}: 96%) deletions. Growth retardation was also compensated and the bodyweights of mice inheriting the additional maternal ∆4.8 kb deletion showed no statistically significant difference from their WT littermates by the age of 6 weeks. This was achieved despite the fact that expression levels of the imprinted genes Snrpn (21%–35%), Snord116 (8%), Snord115 (10%), and Ndn (28%) from the maternal ∆4.8 kb allele were significantly lower compared to wild-type mice ^[99].

Another strategy applied was the re-activation of imprinted PWScr non-protein coding genes from the maternal allele by insertion of the regulatory LoxP cassette 5′- to the Snord116 gene cluster in the PWScr^m+/p− mouse model (Table 1) ^[97]. The PWScr^{m5′LoxP/p−} mice showed a mild growth delay between postnatal day 7 and 19, but over time, gained more weight than their PWScr^m+/p− siblings; weight differences to wild-type littermates became insignificant by postnatal day 21. Although the expression levels of Snord116 and Ipw-A non-protein coding RNAs from the maternal allele were reduced by 7.5 and 12-fold, respectively, it apparently was sufficient to rescue the growth retardation phenotype. The inserted 5′LoxP cassette in PWScr^{m5′LoxP/p−} mice results in ubiquitous transcriptional activation of Snord116 and Snord115 gene clusters from the maternal allele. Expression of Snord64 RNA and protein coding genes at the PWS locus was not perturbed. Although Snord116 was detected in the glial cells of PWScr^{m5′LoxP/p−} mice, the overall brain areas with neuronal snoRNA expression between KI and wild type mice was quite similar ^[97]. This was the first experimental evidence showing that expression of non-protein coding RNAs is primarily causative of growth retardation in mice and potentially PWS in patients. However, the functional significance of the Snord116 or long RNAs consisting of alternatively spliced Ipw-A exons in the PWScr locus or both RNAs is yet to be investigated ^[97].

14. Conclusions

Despite over two decades of investigations, we still lack an in vivo animal model that adequately displays the entire spectrum of PWS symptoms, especially during the second phase that includes obesity. The data supporting a hyperphagic, adult-onset obesity phenotype in mice remains weak at best, with researchers reporting conflicting results despite having used the same knockout strain ^[43]^[91]. While some of the conflicting results could be explained by the different methods used to normalize food consumption to respective body weight, this is a far cry from the late-stage morbid obesity observed in patients. This not only shapes the public perception of the disease; it is also the main underlying factor for increased mortality^[20].

In general, the differences between various animal models that affect the same gene must also be scrutinized. The use of experimental animals with various genetic backgrounds is known to lead to significant phenotypic differences (see for example ^[149]). There are experimental, even interpretational variances between laboratories leading to reports of different phenotypes. In different models of gene depleted animals, the target gene is only partially inactivated. If this results, for example, in the expression of a defective (e.g., truncated) gene product, the latter may convey “side” effects. Alternatively, a truncated gene product (or one “rescued” by spicing) still might be functional to various degrees. Finally, off target events, e.g., during propagation in cell culture is a scary but rarely recognized possibility of observing different phenotypes.

Modelling of PWS in mice is complicated by the complexity of the affected region itself, which spans more than 1.5 Mb and contains several genes, quite a few with an associated phenotype of their own. At least for the protein-coding genes, the sequence similarity between mice and humans seems to correlate with functional similarity, as the respective mouse models display a comparable phenotype ^[33]. The vast majority of human patients are affected by a disruption of these genes in addition to loss of the functionally elusive non-protein coding RNAs and transcripts. The existing mouse models led to a better understanding of the underlying pathophysiological mechanisms and some were tested within a number of ongoing pharmacological trials in search of therapeutic agents ^[150].

For the non-protein coding transcripts, it is more complicated still. Their mechanistic function is unknown, although all insights gained thus far suggest that they are of importance in both species ^[151]. Since even rare, small deletions in human patients encompassing nothing more than non-protein coding genes results in the manifestation of core symptoms typical to PWS, further research focusing on the PWScr region with emphasis on the encoded RNAs and transcripts should eventually elucidate a causative mechanism of the disease ^[34]^[35]^[36]^[37]^[38]^[39].

The first generation of compensatory models are in agreement with the identification of the minimal critical region responsible for the PWS phenotype in mice. One of the important insights gained from those models is that transcript localization, proper processing and quantity—but only to a certain degree ^[97]—are of vital importance. This should be taken into account for prospective models; for example, the natural organization of respective genes should be mimicked as a tandemly repetitive cluster. Moreover, the successful re-activation of the imprinted maternal allele proved to be an option if and when the necessary genome-editing methods are refined enough and deemed save for human application. This could become a feasible therapeutic strategy and an elegant solution for all patients regardless of respective cause, i.e., deletion or maternal uniparental disomy (UPD), since at least one functional allele is always present.

Funding

This work was supported by the Deutsche Forschungsgemeinschaft (DFG) (RO5622/1-1 to TSR and SK259/2-1 to BVS).

Acknowledgments

We thank Stephanie Klco-Brosius for manuscript editing. We apologize to those researches whose contributions could not be cited due to the space limitations.

Conflicts of Interest

The authors declare no conflict of interest.

This entry is adapted from the peer-reviewed paper 10.3390/ijms22073613

References

McCandless, S.E.; Health Supervision for Children With Prader-Willi Syndrome. PEDIATRICS 2010, 127, 195-204, 10.1542/peds.2010-2820.
Suzanne B. Cassidy; Stuart Schwartz; Jennifer L. Miller; Daniel J. Driscoll; Prader-Willi syndrome. Genetics in Medicine 2011, 14, 10-26, 10.1038/gim.0b013e31822bead0.
Louisa Kalsner; Stormy J. Chamberlain; Prader-Willi, Angelman, and 15q11-q13 Duplication Syndromes. Pediatric Clinics of North America 2015, 62, 587-606, 10.1016/j.pcl.2015.03.004.
M. A. Angulo; Merlin G Butler; M. E. Cataletto; Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings. Journal of Endocrinological Investigation 2015, 38, 1249-1263, 10.1007/s40618-015-0312-9.
Merlin G. Butler; Jennifer L. Miller; Janice L. Forster; Prader-Willi Syndrome - Clinical Genetics, Diagnosis and Treatment Approaches: An Update. Current Pediatric Reviews 2019, 15, 207-244, 10.2174/1573396315666190716120925.
C.F. Rocha; C.L.A. Paiva; Mini-Review Prader-Willi-like phenotypes: a systematic review of their chromosomal abnormalities. Genetics and Molecular Research 2014, 13, 2290-2298, 10.4238/2014.march.31.9.
Soo-Jeong Kim; Jennifer L Miller; Paul J Kuipers; Jennifer Ruth German; Arthur L Beaudet; Trilochan Sahoo; Daniel J Driscoll; Unique and atypical deletions in Prader–Willi syndrome reveal distinct phenotypes. European Journal of Human Genetics 2011, 20, 283-290, 10.1038/ejhg.2011.187.
Jennifer L. Miller; Christy H. Lynn; Danielle C. Driscoll; Anthony P. Goldstone; June-Anne Gold; Virginia Kimonis; Elisabeth Dykens; Merlin G. Butler; Jonathan J. Shuster; Daniel J. Driscoll; et al. Nutritional phases in Prader-Willi syndrome. American Journal of Medical Genetics Part A 2011, 155, 1040-1049, 10.1002/ajmg.a.33951.
Christina Kanaka-Gantenbein; Christina Kogia; Mohamed Badawy Abdel-Naser; George P. Chrousos; Skin manifestations of growth hormone-induced diseases. Reviews in Endocrine and Metabolic Disorders 2016, 17, 259-267, 10.1007/s11154-016-9378-8.
Antonino Crinò; Danilo Fintini; Sarah Bocchini; Graziano Grugni; Obesity management in Prader–Willi syndrome: current perspectives. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2018, ume 11, 579-593, 10.2147/dmso.s141352.
Elisabeth M. Dykens; Elizabeth Roof; Hailee Hunt-Hawkins; Christopher Daniell; Sarah Jurgensmeyer; Profiles and trajectories of impaired social cognition in people with Prader-Willi syndrome. PLoS ONE 2019, 14, e0223162, 10.1371/journal.pone.0223162.
Régis Afonso Costa; Igor Ribeiro Ferreira; Hiago Azevedo Cintra; Leonardo Henrique Ferreira Gomes; Letícia Da Cunha Guida; Genotype-Phenotype Relationships and Endocrine Findings in Prader-Willi Syndrome. Frontiers in Endocrinology 2019, 10, 864, 10.3389/fendo.2019.00864.
Chong Kun Cheon; Genetics of Prader-Willi syndrome and Prader-Will-Like syndrome. Annals of Pediatric Endocrinology & Metabolism 2016, 21, 126-135, 10.6065/apem.2016.21.3.126.
Driscoll DJ, Miller JL, Schwartz S, Cassidy SB. Prader-Willi Syndrome.; Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A, Eds.; GeneReviews® [Internet].: Seattle (WA): University of Washington, Seattle; 1993–2021., 1998 Oct 6 [updated 2017 Dec 14]; pp. PMID: 20301505.
Tess Lionti; Susan M. Reid; Susan M. White; Margaret M. Rowell; A population-based profile of 160 Australians with Prader-Willi syndrome: Trends in diagnosis, birth prevalence and birth characteristics. American Journal of Medical Genetics Part A 2014, 167, 371-378, 10.1002/ajmg.a.36845.
Annick Vogels; Jenneke Van Den Ende; Kathelijne Keymolen; Geert Mortier; Koenraad Devriendt; Eric Legius; Jean-Pierre Fryns; Minimum prevalence, birth incidence and cause of death for Prader–Willi syndrome in Flanders. European Journal of Human Genetics 2003, 12, 238-240, 10.1038/sj.ejhg.5201135.
J V Butler; J E Whittington; A J Holland; H Boer; D Clarke; T Webb; Prevalence of, and risk factors for, physical ill-health in people with Prader-Willi syndrome: a population-based study. Developmental Medicine & Child Neurology 2007, 44, 248-255, 10.1111/j.1469-8749.2002.tb00800.x.
Merlin G. Butler; Ann M. Manzardo; Janalee Heinemann; Carolyn Loker; James Loker; Causes of death in Prader-Willi syndrome: Prader-Willi Syndrome Association (USA) 40-year mortality survey. Genetics in Medicine 2016, 19, 635-642, 10.1038/gim.2016.178.
Dibia Liz Pacoricona Alfaro; Perrine Lemoine; Virginie Ehlinger; Catherine Molinas; Gwénaëlle Diene; Marion Valette; Graziella Pinto; Muriel Coupaye; Christine Poitou-Bernert; Denise Thuilleaux; et al. Causes of death in Prader-Willi syndrome: lessons from 11 years’ experience of a national reference center. Orphanet Journal of Rare Diseases 2019, 14, 1-10, 10.1186/s13023-019-1214-2.
Jennifer Proffitt; Kathryn Osann; Barbara McManus; Virginia E. Kimonis; Janalee Heinemann; Merlin G. Butler; David A. Stevenson; June‐Anne Gold; Contributing factors of mortality in Prader–Willi syndrome. American Journal of Medical Genetics Part A 2018, 179, 196-205, 10.1002/ajmg.a.60688.
Graziano Grugni; Alessandro Sartorio; Antonino Crinò; Growth hormone therapy for Prader–Willi syndrome: challenges and solutions. Therapeutics and Clinical Risk Management 2016, 12, 873-881, 10.2147/tcrm.s70068.
Mikaela Frixou; Diane Vlek; Angela K. Lucas‐Herald; Lindsay Keir; Andreas Kyriakou; M. Guftar Shaikh; The use of growth hormone therapy in adults with Prader‐Willi syndrome: A systematic review. Clinical Endocrinology 2020, 94, 645-655, 10.1111/cen.14372.
Rebecca M. Harris; Diane E.J. Stafford; Prader Willi syndrome. Current Opinion in Endocrinology, Diabetes & Obesity 2020, 27, 56-62, 10.1097/med.0000000000000517.
Qiming Tan; Camila E. Orsso; Edward C. Deehan; Lucila Triador; Catherine J. Field; Hein Min Tun; Joan C. Han; Timo D. Müller; Andrea M. Haqq; Current and emerging therapies for managing hyperphagia and obesity in Prader‐Willi syndrome: A narrative review. Obesity Reviews 2019, 21, e12992, 10.1111/obr.12992.
Robert D. Nicholls; Joan H. M. Knoll; Merlin G. Butler; Susan Karam; Marc Lalande; Genetic imprinting suggested by maternal heterodisomy in non-deletion Prader-Willi syndrome. Nature 1989, 342, 281-285, 10.1038/342281a0.
Merlin G. Butler; Genomic imprinting disorders in humans: a mini-review. Journal of Assisted Reproduction and Genetics 2009, 26, 477-486, 10.1007/s10815-009-9353-3.
Michaela Wawrzik; Unga Arifa Unmehopa; Dick Frans Swaab; Johannes Van De Nes; Karin Buiting; Bernhard Horsthemke; The C15orf2 gene in the Prader–Willi syndrome region is subject to genomic imprinting and positive selection. neurogenetics 2009, 11, 153-161, 10.1007/s10048-009-0231-z.
Elizabeth J. Bhoj; Farrah Rajabi; Samuel W. Baker; Avni Santani; Wen-Hann Tan; Imprinted genes in clinical exome sequencing: Review of 538 cases and exploration of mouse-human conservation in the identification of novel human disease loci. European Journal of Medical Genetics 2020, 63, 103903, 10.1016/j.ejmg.2020.103903.
Emma D. Spikol; Caroline E. Laverriere; Maya Robnett; Gabriela Carter; Erin Wolfe; Eric Glasgow; Zebrafish Models of Prader-Willi Syndrome: Fast Track to Pharmacotherapeutics. Diseases 2016, 4, 13, 10.3390/diseases4010013.
Renée Van Amerongen; Martijn Nawijn; Jonathan Franca-Koh; John Zevenhoven; Hanneke Van Der Gulden; Jos Jonkers; Anton Berns; Frat is dispensable for canonical Wnt signaling in mammals. Genes & Development 2005, 19, 425-430, 10.1101/gad.326705.
Lisa C. Neumann; Nathalie Feiner; Axel Meyer; Karin Buiting; Bernhard Horsthemke; The imprinted NPAP1 gene in the Prader-Willi syndrome region belongs to a POM121-related family of retrogenes.. Genome Biology and Evolution 2014, 6, 344-51, 10.1093/gbe/evu019.
Lisa C. Neumann; Yolanda Markaki; Emil Mladenov; Daniel Hoffmann; Karin Buiting; Bernhard Horsthemke; The imprinted NPAP1/C15orf2 gene in the Prader–Willi syndrome region encodes a nuclear pore complex associated protein. Human Molecular Genetics 2012, 21, 4038-4048, 10.1093/hmg/dds228.
Sandrina Bervini; Herbert Herzog; Mouse models of Prader–Willi Syndrome: A systematic review. Frontiers in Neuroendocrinology 2013, 34, 107-119, 10.1016/j.yfrne.2013.01.002.
Trilochan Sahoo; Daniela Del Gaudio; Jennifer R German; Marwan Shinawi; Sarika U Peters; Richard E Person; Adolfo D Garnica; Sau Wai Cheung; Arthur L Beaudet; Prader-Willi phenotype caused by paternal deficiency for the HBII-85 C/D box small nucleolar RNA cluster. Nature Genetics 2008, 40, 719-721, 10.1038/ng.158.
Adam J. De Smith; Carolin Purmann; Robin G. Walters; Richard J. Ellis; Susan E. Holder; Mieke M. Van Haelst; Angela F. Brady; Una L. Fairbrother; Mehul Dattani; Julia M. Keogh; et al. A deletion of the HBII-85 class of small nucleolar RNAs (snoRNAs) is associated with hyperphagia, obesity and hypogonadism. Human Molecular Genetics 2009, 18, 3257-3265, 10.1093/hmg/ddp263.
Angela L Duker; Blake C Ballif; Erawati V Bawle; Richard E Person; Sangeetha Mahadevan; Sarah Alliman; Regina Thompson; Ryan N Traylor; Bassem A Bejjani; Lisa G Shaffer; et al. Paternally inherited microdeletion at 15q11.2 confirms a significant role for the SNORD116 C/D box snoRNA cluster in Prader–Willi syndrome. European Journal of Human Genetics 2010, 18, 1196-1201, 10.1038/ejhg.2010.102.
Eric Bieth; Sanaa Eddiry; Véronique Gaston; Françoise Lorenzini; Alexandre Buffet; Françoise Conte Auriol; Catherine Molinas; Dorothée Cailley; Caroline Rooryck; Benoit Arveiler; et al. Highly restricted deletion of the SNORD116 region is implicated in Prader–Willi Syndrome. European Journal of Human Genetics 2014, 23, 252-255, 10.1038/ejhg.2014.103.
Paolo Fontana; M. Grasso; Fabio Acquaviva; E. Gennaro; M.L. Galli; M. Falco; F. Scarano; G. Scarano; Fortunato Lonardo; SNORD116 deletions cause Prader-Willi syndrome with a mild phenotype and macrocephaly. Clinical Genetics 2017, 92, 440-443, 10.1111/cge.13005.
Qiming Tan; Kathryn J. Potter; Lisa Cole Burnett; Camila E. Orsso; Mark Inman; Davis C. Ryman; Andrea M. Haqq; Prader–Willi-Like Phenotype Caused by an Atypical 15q11.2 Microdeletion. Genes 2020, 11, 128, 10.3390/genes11020128.
J. M. Gabriel; M. Merchant; T. Ohta; Y. Ji; R. G. Caldwell; M. J. Ramsey; J. D. Tucker; R. Longnecker; R. D. Nicholls; A transgene insertion creating a heritable chromosome deletion mouse model of Prader-Willi and Angelman syndromes. Proceedings of the National Academy of Sciences 1999, 96, 9258-9263, 10.1073/pnas.96.16.9258.
T.-F. Tsai; Y.-H. Jiang; J. Bressler; D. Armstrong; A. L. Beaudet; Paternal Deletion from Snrpn to Ube3a in the Mouse Causes Hypotonia, Growth Retardation and Partial Lethality and Provides Evidence for a Gene Contributing to Prader-Willi Syndrome. Human Molecular Genetics 1999, 8, 1357-1364, 10.1093/hmg/8.8.1357.
Boris V Skryabin; Leonid V Gubar; Birte Seeger; Jana Pfeiffer; Sergej Handel; Thomas Robeck; Elena Karpova; Timofey Rozhdestvensky; Jürgen Brosius; Deletion of the MBII-85 snoRNA Gene Cluster in Mice Results in Postnatal Growth Retardation. PLOS Genetics 2007, 3, e235, 10.1371/journal.pgen.0030235.
Feng Ding; Hong Hua Li; Shengwen Zhang; Nicola M. Solomon; Sally A. Camper; Pinchas Cohen; Uta Francke; SnoRNA Snord116 (Pwcr1/MBII-85) Deletion Causes Growth Deficiency and Hyperphagia in Mice. PLoS ONE 2008, 3, e1709-e1709, 10.1371/journal.pone.0001709.
Jade Hebras; Virginie Marty; Jean Personnaz; Pascale Mercier; Nicolai Krogh; Henrik Nielsen; Marion Aguirrebengoa; Hervé Seitz; Jean-Phillipe Pradere; Bruno P Guiard; et al. Reassessment of the involvement of Snord115 in the serotonin 2c receptor pathway in a genetically relevant mouse model. eLife 2020, 9, e60862, 10.7554/elife.60862.
Tao Yang; Todd E. Adamson; James L. Resnick; Stuart Leff; Rachel Wevrick; Uta Francke; Nancy A. Jenkins; Neal G. Copeland; Camilynn I. Brannan; A mouse model for Prader-Willi syndrome imprinting-centre mutations. Nature Genetics 1998, 19, 25-31, 10.1038/ng0598-25.
Jan Bressler; Ting-Fen Tsai; Mei-Yi Wu; Shih-Feng Tsai; Maricela A. Ramirez; Dawna Armstrong; Arthur L. Beaudet; The SNRPN promoter is not required for genomic imprinting of the Prader-Willi/Angelman domain in mice. Nature Genetics 2001, 28, 232-240, 10.1038/90067.
Amanda J. DuBose; Emily Y. Smith; Thomas P. Yang; Karen A. Johnstone; James L. Resnick; A new deletion refines the boundaries of the murine Prader-Willi syndrome imprinting center. Human Molecular Genetics 2011, 20, 3461-3466, 10.1093/hmg/ddr262.
Matthieu Gérard; Lidia Hernandez; Rachel Wevrick; Colin L. Stewart; Disruption of the mouse necdin gene results in early post-natal lethality. Nature Genetics 1999, 23, 199-202, 10.1038/13828.
Ken-Ichiro Kuwako; Akari Hosokawa; Isao Nishimura; Taichi Uetsuki; Masashi Yamada; Shigeyuki Nada; Masato Okada; Kazuaki Yoshikawa; Disruption of the Paternal Necdin Gene Diminishes TrkA Signaling for Sensory Neuron Survival. The Journal of Neuroscience 2005, 25, 7090-7099, 10.1523/jneurosci.2083-05.2005.
Françoise Muscatelli; Djoher Nora Abrous; Annick Massacrier; Irène Boccaccio; Michel Le Moal; Pierrre Cau; Harold Cremer; Disruption of the mouse Necdin gene results in hypothalamic and behavioral alterations reminiscent of the human Prader-Willi syndrome.. Human Molecular Genetics 2000, 9, 3101-3110, 10.1093/hmg/9.20.3101.
Ting-Fen Tsai; Dawna Armstrong; Arthur L. Beaudet; Necdin-deficient mice do not show lethality or the obesity and infertility of Prader-Willi syndrome. Nature Genetics 1999, 22, 15-16, 10.1038/8722.
Fabienne Schaller; Françoise Watrin; Rachel Sturny; Annick Massacrier; Pierre Szepetowski; Françoise Muscatelli; A single postnatal injection of oxytocin rescues the lethal feeding behaviour in mouse newborns deficient for the imprinted Magel2 gene. Human Molecular Genetics 2010, 19, 4895-4905, 10.1093/hmg/ddq424.
Serguei V Kozlov; James W Bogenpohl; Maureen P Howell; Rachel Wevrick; Satchin Panda; John B HogenEsch; Louis J Muglia; Russell N Van Gelder; Erik D Herzog; Colin L Stewart; et al. The imprinted gene Magel2 regulates normal circadian output. Nature Genetics 2007, 39, 1266-1272, 10.1038/ng2114.
Chuanyin Li; Wenli Lu; Liguang Yang; Zhengwei Li; Xiaoyi Zhou; Rong Guo; Junqi Wang; Zhebao Wu; Zhiya Dong; Guang Ning; et al. MKRN3 regulates the epigenetic switch of mammalian puberty via ubiquitination of MBD3. National Science Review 2020, 7, 671-685, 10.1093/nsr/nwaa023.
Bruce M. Cattanach; Jacqueline A. Barr; Edward P. Evans; Michael Burtenshaw; Colin V. Beechey; Stuart E. Leff; Camilynn I. Brannan; Neal G. Copeland; Nancy A. Jenkins; Janet Jones; et al. A candidate mouse model for Prader–Willi syndrome which shows an absence of Snrpn expression. Nature Genetics 1992, 2, 270-274, 10.1038/ng1292-270.
Mihaela Stefan; Kathryn C Claiborn; Edyta Stasiek; Jing-Hua Chai; Tohru Ohta; Richard Longnecker; John M Greally; Robert D Nicholls; Genetic mapping of putative Chrna7 and Luzp2 neuronal transcriptional enhancers due to impact of a transgene-insertion and 6.8 Mb deletion in a mouse model of Prader-Willi and Angelman syndromes. BMC Genomics 2005, 6, 157, 10.1186/1471-2164-6-157.
M. Stefan; H. Ji; R. A. Simmons; D. E. Cummings; R. S. Ahima; M. I. Friedman; R. D. Nicholls; Hormonal and Metabolic Defects in a Prader-Willi Syndrome Mouse Model with Neonatal Failure to Thrive. Endocrinology 2005, 146, 4377-4385, 10.1210/en.2005-0371.
Mihaela Stefan; Rebecca A. Simmons; Suzanne Bertera; Massimo Trucco; Farzad Esni; Peter Drain; Robert D. Nicholls; Global deficits in development, function, and gene expression in the endocrine pancreas in a deletion mouse model of Prader-Willi syndrome. American Journal of Physiology-Endocrinology and Metabolism 2011, 300, E909-E922, 10.1152/ajpendo.00185.2010.
Jocelyn M. Bischof; Colin L. Stewart; Rachel Wevrick; Inactivation of the mouse Magel2 gene results in growth abnormalities similar to Prader-Willi syndrome. Human Molecular Genetics 2007, 16, 2713-2719, 10.1093/hmg/ddm225.
Rebecca E. Mercer; Rachel Wevrick; Loss of Magel2, a Candidate Gene for Features of Prader-Willi Syndrome, Impairs Reproductive Function in Mice. PLOS ONE 2009, 4, e4291, 10.1371/journal.pone.0004291.
Rebecca E. Mercer; Erin M. Kwolek; Jocelyn M. Bischof; Matthijs Van Eede; R. Mark Henkelman; Rachel Wevrick; Regionally reduced brain volume, altered serotonin neurochemistry, and abnormal behavior in mice null for the circadian rhythm output geneMagel2. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2009, 150B, 1085-1099, 10.1002/ajmg.b.30934.
Rebecca E. Mercer; Sheldon D. Michaelson; Melissa J. S. Chee; Tanya A. Atallah; Rachel Wevrick; William F. Colmers; Magel2 Is Required for Leptin-Mediated Depolarization of POMC Neurons in the Hypothalamic Arcuate Nucleus in Mice. PLOS Genetics 2013, 9, e1003207, 10.1371/journal.pgen.1003207.
Deanna M. Arble; Joshua W. Pressler; Joyce Sorrell; Rachel Wevrick; Darleen A. Sandoval; Sleeve gastrectomy leads to weight loss in the Magel2 knockout mouse. Surgery for Obesity and Related Diseases 2016, 12, 1795-1802, 10.1016/j.soard.2016.04.023.
Julien Maillard; Soyoung Park; Sophie Croizier; Charlotte Vanacker; Joshua H. Cook; Vincent Prevot; Maithe Tauber; Sebastien G. Bouret; Loss of Magel2 impairs the development of hypothalamic Anorexigenic circuits. Human Molecular Genetics 2016, 25, 3208-3215, 10.1093/hmg/ddw169.
Tishani Methsala Wijesuriya; Leentje De Ceuninck; Delphine Masschaele; Matthea R Sanderson; Karin Vanessa Carias; Jan Tavernier; Rachel Wevrick; The Prader-Willi syndrome proteins MAGEL2 and necdin regulate leptin receptor cell surface abundance through ubiquitination pathways. Human Molecular Genetics 2017, 26, 4215-4230, 10.1093/hmg/ddx311.
Merve Oncul; Pelin Dilsiz; Edanur Ates Oz; Tayfun Ates; Iltan Aklan; Esref Celik; Nilufer Sayar Atasoy; Deniz Atasoy; Impaired melanocortin pathway function in Prader–Willi syndrome gene-Magel2 deficient mice. Human Molecular Genetics 2018, 27, 3129-3136, 10.1093/hmg/ddy216.
Saja Baraghithy; Reem Smoum; Adi Drori; Rivka Hadar; Asaad Gammal; Shira Hirsch; Malka Attar-Namdar; Alina Nemirovski; Yankel Gabet; Yshaia Langer; et al. Magel2 Modulates Bone Remodeling and Mass in Prader‐Willi Syndrome by Affecting Oleoyl Serine Levels and Activity. Journal of Bone and Mineral Research 2018, 34, 93-105, 10.1002/jbmr.3591.
Emeline Crutcher; Rituraj Pal; Fatemeh Naini; Ping Zhang; Magdalena Laugsch; Jean Kim; Aleksandar Bajic; Christian P. Schaaf; mTOR and autophagy pathways are dysregulated in murine and human models of Schaaf-Yang syndrome. Scientific Reports 2019, 9, 15935, 10.1038/s41598-019-52287-2.
Miki Igarashi; Vidya Narayanaswami; Virginia Kimonis; Pietro M. Galassetti; Fariba Oveisi; Kwang-Mook Jung; Daniele Piomelli; Dysfunctional oleoylethanolamide signaling in a mouse model of Prader-Willi syndrome. Pharmacological Research 2017, 117, 75-81, 10.1016/j.phrs.2016.12.024.
Chloe Luck; Martha H. Vitaterna; Rachel Wevrick; Dopamine pathway imbalance in mice lacking Magel2, a Prader-Willi syndrome candidate gene.. Behavioral Neuroscience 2016, 130, 448-459, 10.1037/bne0000150.
Tayfun Ates; Merve Oncul; Pelin Dilsiz; Iskalen Cansu Topcu; Cihan Civan Civas; Muhammed Ikbal Alp; Iltan Aklan; Edanur Ates Oz; Yavuz Yavuz; Bayram Yilmaz; et al. Inactivation of Magel2 suppresses oxytocin neurons through synaptic excitation-inhibition imbalance. Neurobiology of Disease 2019, 121, 58-64, 10.1016/j.nbd.2018.09.017.
Helen Chen; A. Kaitlyn Victor; Jonathon Klein; Klementina Fon Tacer; Derek J.C. Tai; Celine De Esch; Alexander Nuttle; Jamshid Temirov; Lisa C. Burnett; Michael Rosenbaum; et al. Loss of MAGEL2 in Prader-Willi syndrome leads to decreased secretory granule and neuropeptide production. JCI Insight 2020, 5, e138576, 10.1172/jci.insight.138576.
Hamid Meziane; Fabienne Schaller; Sylvian Bauer; Claude Villard; Valery Matarazzo; Fabrice Riet; Gilles Guillon; Daniel Lafitte; Michel G. Desarmenien; Maithé Tauber; et al. An Early Postnatal Oxytocin Treatment Prevents Social and Learning Deficits in Adult Mice Deficient for Magel2, a Gene Involved in Prader-Willi Syndrome and Autism. Biological Psychiatry 2015, 78, 85-94, 10.1016/j.biopsych.2014.11.010.
Daisuke Ieda; Yutaka Negishi; Tomomi Miyamoto; Yoshikazu Johmura; Natsuko Kumamoto; Kohji Kato; Ichiro Miyoshi; Makoto Nakanishi; Shinya Ugawa; Hisashi Oishi; et al. Two mouse models carrying truncating mutations in Magel2 show distinct phenotypes. PLOS ONE 2020, 15, e0237814, 10.1371/journal.pone.0237814.
Sébastien Zanella; Françoise Watrin; Saïda Mebarek; Fabienne Marly; Michel Roussel; Catherine Gire; Gwenaëlle Diene; Maïté Tauber; Françoise Muscatelli; Gérard Hilaire; et al. Necdin Plays a Role in the Serotonergic Modulation of the Mouse Respiratory Network: Implication for Prader-Willi Syndrome. The Journal of Neuroscience 2008, 28, 1745-1755, 10.1523/jneurosci.4334-07.2008.
Jun Ren; Syann Lee; Silvia Pagliardini; Matthieu Gérard; Colin L. Stewart; John J. Greer; Rachel Wevrick; Absence of Ndn, Encoding the Prader-Willi Syndrome-Deleted Gene necdin, Results in Congenital Deficiency of Central Respiratory Drive in Neonatal Mice. The Journal of Neuroscience 2003, 23, 1569-1573, 10.1523/JNEUROSCI.23-05-01569.2003.
Anne Rieusset; Fabienne Schaller; Unga Unmehopa; Valery Matarazzo; Françoise Watrin; Matthias Linke; Béatrice Georges; Jocelyn Bischof; Femke Dijkstra; Monique Bloemsma; et al. Stochastic Loss of Silencing of the Imprinted Ndn/NDN Allele, in a Mouse Model and Humans with Prader-Willi Syndrome, Has Functional Consequences. PLOS Genetics 2013, 9, e1003752, 10.1371/journal.pgen.1003752.
Valéry Matarazzo; Laura Caccialupi; Fabienne Schaller; Yuri Shvarev; Nazim Kourdougli; Alessandra Bertoni; Clément Menuet; Nicolas Voituron; Evan Deneris; Patricia Gaspar; et al. Necdin shapes serotonergic development and SERT activity modulating breathing in a mouse model for Prader-Willi syndrome. eLife 2017, 6, e32640, 10.7554/elife.32640.
Rui-Ni Wu; Wei-Chen Hung; Ching-Tsuey Chen; Li-Ping Tsai; Wen-Sung Lai; Ming-Yuan Min; Shi-Bing Wong; Firing activity of locus coeruleus noradrenergic neurons decreases in necdin-deficient mice, an animal model of Prader–Willi syndrome. Journal of Neurodevelopmental Disorders 2020, 12, 1-12, 10.1186/s11689-020-09323-4.
RenBin Lu; Yufan Dong; Jia-Da Li; Necdin regulates BMAL1 stability and circadian clock through SGT1-HSP90 chaperone machinery. Nucleic Acids Research 2020, 48, 7944-7957, 10.1093/nar/gkaa601.
Stormy J. Chamberlain; Karen A. Johnstone; Amanda J. DuBose; Thomas A. Simon; Marisa S. Bartolomei; James L. Resnick; Camilynn I. Brannan; Evidence for genetic modifiers of postnatal lethality in PWS-IC deletion mice. Human Molecular Genetics 2004, 13, 2971-2977, 10.1093/hmg/ddh314.
Dinko Relkovic; Christine M. Doe; Trevor Humby; Karen A. Johnstone; James L. Resnick; Anthony J. Holland; Jim J. Hagan; Lawrence S. Wilkinson; Anthony R. Isles; Behavioural and cognitive abnormalities in an imprinting centre deletion mouse model for Praderâ€“Willi syndrome. European Journal of Neuroscience 2010, 31, 156-164, 10.1111/j.1460-9568.2009.07048.x.
Christine M. Doe; Dinko Relkovic; Alastair S. Garfield; Jeffrey W. Dalley; David E.H. Theobald; Trevor Humby; Lawrence S. Wilkinson; Anthony R. Isles; Loss of the imprinted snoRNA mbii-52 leads to increased 5htr2c pre-RNA editing and altered 5HT2CR-mediated behaviour. Human Molecular Genetics 2009, 18, 2140-2148, 10.1093/hmg/ddp137.
Jennifer R. Davies; Trevor Humby; Dominic M. Dwyer; Alastair S. Garfield; Hannah Furby; Lawrence S. Wilkinson; Timothy N C Wells; Anthony R. Isles; Calorie seeking, but not hedonic response, contributes to hyperphagia in a mouse model for Prader-Willi syndrome. European Journal of Neuroscience 2015, 42, 2105-2113, 10.1111/ejn.12972.
Jennifer R Davies; Lawrence S Wilkinson; Anthony R Isles; Trevor Humby; Prader-Willi syndrome imprinting centre deletion mice have impaired baseline and 5-HT2CR-mediated response inhibition.. Human Molecular Genetics 2019, 28, 3013-3023, 10.1093/hmg/ddz100.
Dinko Relkovic; Trevor Humby; Jim J. Hagan; Lawrence S. Wilkinson; Anthony R. Isles; Enhanced appetitive learning and reversal learning in a mouse model for Prader-Willi syndrome.. Behavioral Neuroscience 2012, 126, 488-492, 10.1037/a0028155.
Karen A. Johnstone; Amanda J. DuBose; Christopher R. Futtner; Michael D. Elmore; Camilynn I. Brannan; James L. Resnick; A human imprinting centre demonstrates conserved acquisition but diverged maintenance of imprinting in a mouse model for Angelman syndrome imprinting defects. Human Molecular Genetics 2005, 15, 393-404, 10.1093/hmg/ddi456.
Marta Pace; Matteo Falappa; Andrea Freschi; Edoardo Balzani; Chiara Berteotti; Viviana Lo Martire; Fatemeh Kaveh; Eivind Hovig; Giovanna Zoccoli; Roberto Amici; et al. Loss of Snord116 impacts lateral hypothalamus, sleep, and food-related behaviors. JCI Insight 2020, 5, e137495, 10.1172/jci.insight.137495.
Glenda Lassi; Lorenzo Priano; Silvia Maggi; Celina Garcia-Garcia; Edoardo Balzani; Nadia El-Assawy; Marco Pagani; Federico Tinarelli; Daniela Giardino; Alessandro Mauro; et al. Deletion of theSnord116/SNORD116Alters Sleep in Mice and Patients with Prader-Willi Syndrome. Sleep 2016, 39, 637-644, 10.5665/sleep.5542.
Anna Adhikari; Nycole A. Copping; Beth Onaga; Michael C. Pride; Rochelle L. Coulson; Mu Yang; Dag H. Yasui; Janine M. LaSalle; Jill L. Silverman; Cognitive deficits in the Snord116 deletion mouse model for Prader-Willi syndrome. Neurobiology of Learning and Memory 2019, 165, 106874, 10.1016/j.nlm.2018.05.011.
Joseph Polex-Wolf; Brian Y.H. Lam; Rachel Larder; John Tadross; Debra Rimmington; Fatima Bosch; Verónica Jiménez Cenzano; Eduard Ayuso; Marcella K.L. Ma; Kara Rainbow; et al. Hypothalamic loss of Snord116 recapitulates the hyperphagia of Prader-Willi syndrome.. Journal of Clinical Investigation 2018, 128, 960-969, 10.1172/JCI97007.
Lisa Cole Burnett; Gabriela Hubner; Charles A Leduc; Michael V Morabito; Jayne F Martin Carli; Rudolph L Leibel; Loss of the imprinted, non-coding Snord116 gene cluster in the interval deleted in the Prader Willi syndrome results in murine neuronal and endocrine pancreatic developmental phenotypes. Human Molecular Genetics 2017, 26, 4606-4616, 10.1093/hmg/ddx342.
Lisa C. Burnett; Charles A. LeDuc; Carlos R. Sulsona; Daniel Paull; Richard Rausch; Sanaa Eddiry; Jayne F. Martin Carli; Michael V. Morabito; Alicja A. Skowronski; Gabriela Hubner; et al. Deficiency in prohormone convertase PC1 impairs prohormone processing in Prader-Willi syndrome. Journal of Clinical Investigation 2016, 127, 293-305, 10.1172/jci88648.
Weston T. Powell; Rochelle L. Coulson; Florence K. Crary; Spencer S. Wong; Robert A. Ach; Peter Tsang; N. Alice Yamada; Dag H. Yasui; Janine M. LaSalle; A Prader–Willi locus lncRNA cloud modulates diurnal genes and energy expenditure. Human Molecular Genetics 2013, 22, 4318-4328, 10.1093/hmg/ddt281.
Yue Qi; Louise Purtell; Melissa Fu; Nicola J. Lee; Julia Aepler; Lei Zhang; Kim Loh; Ronaldo F. Enriquez; Paul A. Baldock; Sergei Zolotukhin; et al. Snord116 is critical in the regulation of food intake and body weight. Scientific Reports 2016, 6, 18614, 10.1038/srep18614.
Louise Purtell; Yue Qi; Lesley Campbell; Amanda Sainsbury; Herbert Herzog; Adult-onset deletion of the Prader-Willi syndrome susceptibility gene Snord116 in mice results in reduced feeding and increased fat mass. Translational Pediatrics 2017, 6, 88-97, 10.21037/tp.2017.03.06.
Timofey S. Rozhdestvensky; Thomas Robeck; Chenna R. Galiveti; Carsten A. Raabe; Birte Seeger; Anna Wolters; Leonid V. Gubar; Jürgen Brosius; Boris V. Skryabin; Maternal transcription of non-protein coding RNAs from the PWS-critical region rescues growth retardation in mice. Scientific Reports 2016, 6, 20398, 10.1038/srep20398.
Rochelle L Coulson; Weston T Powell; Dag H Yasui; Gayathri Dileep; James Resnick; Janine M LaSalle; Prader–Willi locus Snord116 RNA processing requires an active endogenous allele and neuron-specific splicing by Rbfox3/NeuN. Human Molecular Genetics 2018, 27, 4051-4060, 10.1093/hmg/ddy296.
Mei-Yi Wu; Ming Jiang; Xiaodong Zhai; Arthur L. Beaudet; Ray-Chang Wu; An Unexpected Function of the Prader-Willi Syndrome Imprinting Center in Maternal Imprinting in Mice. PLOS ONE 2012, 7, e34348, 10.1371/journal.pone.0034348.
Y. Qi; L. Purtell; M. Fu; L. Zhang; S. Zolotukhin; L. Campbell; H. Herzog; Hypothalamus Specific Re-Introduction of SNORD116 into Otherwise Snord116 Deficient Mice Increased Energy Expenditure. Journal of Neuroendocrinology 2017, 29, e12457, 10.1111/jne.12457.
Jos Jonkers; Renée Van Amerongen; Martin Van Der Valk; Els Robanus-Maandag; Miranda Molenaar; Olivier Destrée; Anton Berns; In vivo analysis of Frat1 deficiency suggests compensatory activity of Frat3. Mechanisms of Development 1999, 88, 183-194, 10.1016/s0925-4773(99)00187-2.
Shin Kobayashi; Takashi Kohda; Hitoshi Ichikawa; Atsuo Ogura; Misao Ohki; Tomoko Kaneko-Ishino; Fumitoshi Ishino; Paternal Expression of a Novel Imprinted Gene, Peg12/Frat3, in the Mouse 7C Region Homologous to the Prader–Willi Syndrome Region. Biochemical and Biophysical Research Communications 2002, 290, 403-408, 10.1006/bbrc.2001.6160.
Ana Paula Abreu; Andrew Dauber; Delanie B. Macedo; Sekoni D. Noel; Vinicius N. Brito; John C. Gill; Priscilla Cukier; Iain R. Thompson; Victor M. Navarro; Priscila C. Gagliardi; et al. Central Precocious Puberty Caused by Mutations in the Imprinted Gene MKRN3. New England Journal of Medicine 2013, 368, 2467-2475, 10.1056/nejmoa1302160.
Deniz Kanber; Jacques C Giltay; Dagmar Wieczorek; Corinna Zogel; Ron Hochstenbach; Almuth Caliebe; Alma Kuechler; Bernhard Horsthemke; Karin Buiting; A paternal deletion of MKRN3, MAGEL2 and NDN does not result in Prader–Willi syndrome. European Journal of Human Genetics 2008, 17, 582-590, 10.1038/ejhg.2008.232.
Syann Lee; Christine L. Walker; Rachel Wevrick; Prader–Willi syndrome transcripts are expressed in phenotypically significant regions of the developing mouse brain. Patterns 2003, 3, 599-609, 10.1016/s1567-133x(03)00113-3.
Syann Lee; Serguei Kozlov; Lidia Hernandez; Stormy J. Chamberlain; Camilynn I. Brannan; Colin L. Stewart; Rachel Wevrick; Expression and imprinting of MAGEL2 suggest a role in Prader-willi syndrome and the homologous murine imprinting phenotype.. Human Molecular Genetics 2000, 9, 1813-1819, 10.1093/hmg/9.12.1813.
Yi-Heng Hao; Jennifer M. Doyle; Saumya Ramanathan; Timothy S. Gomez; Da Jia; Ming Xu; Zhijian J. Chen; Daniel D. Billadeau; Michael K. Rosen; Patrick Ryan Potts; et al. Regulation of WASH-Dependent Actin Polymerization and Protein Trafficking by Ubiquitination. Cell 2013, 152, 1051-1064, 10.1016/j.cell.2013.01.051.
Jennifer M. Doyle; Jinlan Gao; Jiawei Wang; Maojun Yang; Patrick Ryan Potts; MAGE-RING Protein Complexes Comprise a Family of E3 Ubiquitin Ligases. Molecular Cell 2010, 39, 963-974, 10.1016/j.molcel.2010.08.029.
John McCarthy; Philip J. Lupo; Erin Kovar; Megan Rech; Bret Bostwick; Daryl Scott; Katerina Kraft; Tony Roscioli; Joel Charrow; Samantha A. Schrier Vergano; et al. Schaaf-Yang syndrome overview: Report of 78 individuals. American Journal of Medical Genetics Part A 2018, 176, 2564-2574, 10.1002/ajmg.a.40650.
Michael D. Fountain; Emmelien Aten; Megan T. Cho; Jane Juusola; Magdalena A. Walkiewicz; Joseph W. Ray; Fan Xia; Yaping Yang; Brett H. Graham Md; Carlos A. Bacino; et al. The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families. Genetics in Medicine 2016, 19, 45-52, 10.1038/gim.2016.53.
Christian P. Schaaf; Manuel L. Gonzalez-Garay; Fan Xia; Lorraine Potocki; Karen W. Gripp; Baili Zhang; Brock A. Peters; Mark A. McElwain; Radoje Drmanac; Arthur L. Beaudet; et al. Truncating mutations of MAGEL2 cause Prader-Willi phenotypes and autism. Nature Genetics 2013, 45, 1405-1408, 10.1038/ng.2776.
Alysa A. Tennese; Rachel Wevrick; Impaired Hypothalamic Regulation of Endocrine Function and Delayed Counterregulatory Response to Hypoglycemia in Magel2-Null Mice. Endocrinology 2011, 152, 967-978, 10.1210/en.2010-0709.
Michael D. Fountain; Huifang Tao; Chun-An Chen; Jiani Yin; Christian P. Schaaf; Magel2 knockout mice manifest altered social phenotypes and a deficit in preference for social novelty. Genes, Brain and Behavior 2017, 16, 592-600, 10.1111/gbb.12378.
Takaaki Kuwajima; Koichi Hasegawa; Kazuaki Yoshikawa; Necdin Promotes Tangential Migration of Neocortical Interneurons from Basal Forebrain. The Journal of Neuroscience 2010, 30, 3709-3714, 10.1523/jneurosci.5797-09.2010.
Alysa A. Tennese; Christopher B. Gee; Rachel Wevrick; Loss of the Prader‐Willi syndrome protein necdin causes defective migration, axonal outgrowth, and survival of embryonic sympathetic neurons. Developmental Dynamics 2008, 237, 1935-1943, 10.1002/dvdy.21615.
James M. Gabriel; Todd A. Gray; Lisa Stubbs; Shihji Saitoh; Tohru Ohta; Robert D. Nicholls; Structure and function correlations at the imprinted mouse Snrpn locus. Mammalian Genome 1998, 9, 788-793, 10.1007/s003359900868.
Jing-Hua Chai; Devin P. Locke; Tohru Ohta; John M. Greally; Robert D. Nicholls; Retrotransposed genes such as Frat3 in the mouse Chromosome 7C Prader-Willi syndrome region acquire the imprinted status of their insertion site.. Mammalian Genome 2001, 12, 813-821, 10.1007/s00335-001-2083-1.
Jürgen Brosius; Henri Tiedge; Reverse transcriptase: Mediator of genomic plasticity. Virus Genes 1995, 11, 163-179, 10.1007/bf01728656.
C. C. Glenn; S. Saitoh; M. T. Jong; M. M. Filbrandt; U. Surti; D. J. Driscoll; R. D. Nicholls; Gene structure, DNA methylation, and imprinted expression of the human SNRPN gene.. The American Journal of Human Genetics 1996, 58, 335-346, .
Todd A. Gray; Shinji Saitoh; Robert D. Nicholls; An imprinted, mammalian bicistronic transcript encodes two independent proteins. Proceedings of the National Academy of Sciences 1999, 96, 5616-5621, 10.1073/pnas.96.10.5616.
Huiping Li; Pingping Zhao; Qiong Xu; Shifang Shan; Chunchun Hu; Zilong Qiu; Xiu Xu; The autism-related gene SNRPN regulates cortical and spine development via controlling nuclear receptor Nr4a1. Scientific Reports 2016, 6, 29878, 10.1038/srep29878.
Keith Grimaldi; Dianne Gerrelli; Neil G. Sharpe; Torben Lund; David S. Latchman; The intronless mouse gene for the tissue specific splicing protein SmN is a processed pseudogene containing a stop codon after thirty-one amino acids. DNA Sequence 1992, 2, 241-246, 10.3109/10425179209020809.
Moon-Sing Lee; Yu-Shan Lin; Yi-Fang Deng; Wan-Ting Hsu; Chiung-Chun Shen; Yi-Hsin Cheng; Yao-Ting Huang; Chin Li; Modulation of alternative splicing by expression of small nuclear ribonucleoprotein polypeptide N. The FEBS Journal 2014, 281, 5194-5207, 10.1111/febs.13059.
Daniela Bettio; N. Rizzi; D. Giardino; G. Grugni; V. Briscioli; A. Selicorni; F. Carnevale; L. Larizza; FISH analysis in Prader-Willi and Angelman syndrome patients. American Journal of Medical Genetics 1995, 56, 224-228, 10.1002/ajmg.1320560222.
Karin Buiting; Shinji Saitoh; Stephanie Gross; Bärbel Dittrich; Stuart Schwartz; Robert D. Nicholls; Bernhard Horsthemke; Inherited microdeletions in the Angelman and Prader–Willi syndromes define an imprinting centre on human chromosome 15. Nature Genetics 1995, 9, 395-400, 10.1038/ng0495-395.
T. Ohta; T.A. Gray; P.K. Rogan; K. Buiting; J.M. Gabriel; S. Saitoh; B. Muralidhar; B. Bilienska; M. Krajewska-Walasek; D.J. Driscoll; et al. Imprinting-Mutation Mechanisms in Prader-Willi Syndrome. The American Journal of Human Genetics 1999, 64, 397-413, 10.1086/302233.
Chenna R. Galiveti; Carsten A. Raabe; Zoltan Konthur; Timofey S. Rozhdestvensky; Differential regulation of non-protein coding RNAs from Prader-Willi Syndrome locus. Scientific Reports 2014, 4, 6445, 10.1038/srep06445.
Jérôme Cavaillé; Karin Buiting; Martin Kiefmann; Marc Lalande; Camilynn I. Brannan; Bernhard Horsthemke; Jean-Pierre Bachellerie; Jürgen Brosius; Alexander Hüttenhofer; Identification of brain-specific and imprinted small nucleolar RNA genes exhibiting an unusual genomic organization. Proceedings of the National Academy of Sciences 2000, 97, 14311-14316, 10.1073/pnas.250426397.
Jérôme Cavaillé; Box C/D small nucleolar RNA genes and the Prader-Willi syndrome: a complex interplay. WIREs RNA 2017, 8, e1417, 10.1002/wrna.1417.
M. Meguro; Large-scale evaluation of imprinting status in the Prader-Willi syndrome region: an imprinted direct repeat cluster resembling small nucleolar RNA genes. Human Molecular Genetics 2001, 10, 383-394, 10.1093/hmg/10.4.383.
Feng Ding; Yelena Prints; Madhu S. Dhar; Dabney K. Johnson; Carmen Garnacho–Montero; Robert D. Nicholls; Uta Francke; Lack of Pwcr1/MBII-85 snoRNA is critical for neonatal lethality in Prader–Willi syndrome mouse models. Mammalian Genome 2005, 16, 424-431, 10.1007/s00335-005-2460-2.
Rochelle L. Coulson; Dag H. Yasui; Keith W. Dunaway; Benjamin I. Laufer; Annie Vogel Ciernia; Yihui Zhu; Charles E. Mordaunt; Theresa S. Totah; Janine M. LaSalle; Snord116-dependent diurnal rhythm of DNA methylation in mouse cortex. Nature Communications 2018, 9, 1-11, 10.1038/s41467-018-03676-0.
A. Chagraoui; F. Thibaut; M. Skiba; C. Thuillez; M. Bourin; 5-HT2C receptors in psychiatric disorders: A review. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2016, 66, 120-135, 10.1016/j.pnpbp.2015.12.006.
Jose M. Palacios; Angel Pazos; Daniel Hoyer; A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment. Psychopharmacology 2017, 234, 1395-1418, 10.1007/s00213-017-4545-5.
Michael V. Morabito; Randi J. Ulbricht; Richard T. O'neil; David C. Airey; Pengcheng Lu; Bing Zhang; Lily Wang; Ronald B. Emeson; High-Throughput Multiplexed Transcript Analysis Yields Enhanced Resolution of 5-Hydroxytryptamine2CReceptor mRNA Editing Profiles. Molecular Pharmacology 2010, 77, 895-902, 10.1124/mol.109.061903.
Tim D. Werry; Richard LoIacono; Patrick M. Sexton; Arthur Christopoulos; RNA editing of the serotonin 5HT2C receptor and its effects on cell signalling, pharmacology and brain function. Pharmacology & Therapeutics 2008, 119, 7-23, 10.1016/j.pharmthera.2008.03.012.
Shivendra Kishore; The snoRNA HBII-52 Regulates Alternative Splicing of the Serotonin Receptor 2C. Science 2006, 311, 230-232, 10.1126/science.1118265.
Alastair S. Garfield; Jennifer R. Davies; Luke K. Burke; Hannah V. Furby; Lawrence S. Wilkinson; Lora K. Heisler; Anthony R. Isles; Increased alternate splicing of Htr2c in a mouse model for Prader-Willi syndrome leads disruption of 5HT2C receptor mediated appetite. Molecular Brain 2016, 9, 95, 10.1186/s13041-016-0277-4.
Carsten A. Raabe; Reinhard Voss; Delf-Magnus Kummerfeld; Juergen Brosius; Chenna R. Galiveti; Anna Wolters; Jochen Seggewiss; Andreas Huge; Boris V. Skryabin; Timofey S. Rozhdestvensky; et al. Ectopic expression of Snord115 in choroid plexus interferes with editing but not splicing of 5-Ht2c receptor pre-mRNA in mice. Scientific Reports 2019, 9, 4300, 10.1038/s41598-019-39940-6.
Elena G. Bochukova; Katherine Lawler; Sophie Croizier; Julia M. Keogh; Nisha Patel; Garth Strohbehn; Kitty K. Lo; Jack Humphrey; Anita Hokken-Koelega; Layla Damen; et al. A Transcriptomic Signature of the Hypothalamic Response to Fasting and BDNF Deficiency in Prader-Willi Syndrome. Cell Reports 2018, 22, 3401-3408, 10.1016/j.celrep.2018.03.018.
Patrice Vitali; Eugenia Basyuk; Elodie Le Meur; Edouard Bertrand; Françoise Muscatelli; Jérôme Cavaillé; Alexander Huttenhofer; ADAR2-mediated editing of RNA substrates in the nucleolus is inhibited by C/D small nucleolar RNAs. Journal of Cell Biology 2005, 169, 745-753, 10.1083/jcb.200411129.
Jin Nakatani; Kota Tamada; Fumiyuki Hatanaka; Satoko Ise; Hisashi Ohta; Kiyoshi Inoue; Shozo Tomonaga; Yasuhito Watanabe; Yeun Jun Chung; Ruby Banerjee; et al. Abnormal Behavior in a Chromosome- Engineered Mouse Model for Human 15q11-13 Duplication Seen in Autism. Cell 2009, 137, 1235-1246, 10.1016/j.cell.2009.04.024.
Dingding Mo; Carsten A. Raabe; Richard Reinhardt; Juergen Brosius; Timofey S. Rozhdestvensky; Alternative Processing as Evolutionary Mechanism for the Origin of Novel Nonprotein Coding RNAs. Genome Biology and Evolution 2013, 5, 2061-2071, 10.1093/gbe/evt155.
Jürgen Brosius; The Fragmented Gene. Annals of the New York Academy of Sciences 2009, 1178, 186-193, 10.1111/j.1749-6632.2009.05004.x.
Qian Zhang; Gerrit J. Bouma; Kristy McClellan; Stuart Tobet; Hypothalamic expression of snoRNA Snord116 is consistent with a link to the hyperphagia and obesity symptoms of Prader–Willi syndrome. International Journal of Developmental Neuroscience 2012, 30, 479-485, 10.1016/j.ijdevneu.2012.05.005.
John C. Castle; Christopher D. Armour; Martin Löwer; David Haynor; Matthew Biery; Heather Bouzek; Ronghua Chen; Stuart Jackson; Jason M. Johnson; Carol A. Rohl; et al. Digital Genome-Wide ncRNA Expression, Including SnoRNAs, across 11 Human Tissues Using PolyA-Neutral Amplification. PLOS ONE 2010, 5, e11779, 10.1371/journal.pone.0011779.
Boris V. Skryabin; Delf-Magnus Kummerfeld; Leonid Gubar; Birte Seeger; Helena Kaiser; Anja Stegemann; Johannes Roth; Sven G. Meuth; Hermann Pavenstädt; Joanna Sherwood; et al. Pervasive head-to-tail insertions of DNA templates mask desired CRISPR-Cas9–mediated genome editing events. Science Advances 2020, 6, eaax2941, 10.1126/sciadv.aax2941.
Alexander Smirnov; Veniamin Fishman; Anastasia Yunusova; Alexey Korablev; Irina Serova; Boris V Skryabin; Timofey S Rozhdestvensky; Nariman Battulin; DNA barcoding reveals that injected transgenes are predominantly processed by homologous recombination in mouse zygote. Nucleic Acids Research 2019, 48, 719-735, 10.1093/nar/gkz1085.
M Sibilia; E F Wagner; Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 1995, 269, 234-238, 10.1126/science.7618085.
K. Vanessa Carias; Rachel Wevrick; Preclinical Testing in Translational Animal Models of Prader-Willi Syndrome: Overview and Gap Analysis. Molecular Therapy - Methods & Clinical Development 2019, 13, 344-358, 10.1016/j.omtm.2019.03.001.
Matthew A. Kocher; Deborah J. Good; Phylogenetic Analysis of the SNORD116 Locus. Genes 2017, 8, 358, 10.3390/genes8120358.

© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.